UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 1997
------------------
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _______________ to ____________
Commission file number: 0-26642
-------
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 87-0494517
- ---------------------------- ------------------------------------
(State or other jurisdiction (I.R.S. Employer Identification No.)
of incorporation or organization)
320 WAKARA WAY, SALT LAKE CITY, UT 84108
- ------------------------------------------- -----------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (801) 584-3600
--------------
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [ ]
As of November 10, 1997, the registrant had 9,273,971 shares
of common stock outstanding.
MYRIAD GENETICS, INC.
INDEX TO FORM 10-Q
Page
----
PART I - Financial Information
Item 1. Financial Statements.
Condensed Consolidated Balance Sheet as of September 30, 1997
and June 30, 1997 3
Condensed Consolidated Statements of Operations for the three
months ended September 30, 1997 and 1996 4
Condensed Consolidated Statements of Cash Flows for the
three months ended September 30, 1997 and 1996 5
Notes to Condensed Consolidated Financial Statements 6
Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations 7
PART II - Other Information
Item 1. Legal Proceedings 11
Item 2. Changes in Securities 11
Item 3. Defaults Upon Senior Securities 12
Item 4. Submission of Matters to a Vote of Security Holders 12
Item 5. Other Information 12
Item 6. Exhibits and Reports on Form 8-K 12
SIGNATURE(S) 13
2
MYRIAD GENETICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
Sept. 30, 1997
(Unaudited) June 30, 1997
-------------- -------------
Assets
Current assets:
Cash and cash equivalents $ 20,447,227 $ 15,675,763
Marketable investment securities 30,450,929 31,952,315
Prepaid expenses 157,098 446,260
Trade receivables 186,476 183,166
Non-trade receivables 329,663 294,967
------------ ------------
Total current assets 51,571,393 48,552,471
------------ ------------
Equipment and leasehold improvements:
Equipment 13,682,417 13,124,937
Leasehold improvements 2,242,128 2,075,308
------------ ------------
15,924,545 15,200,245
Less accumulated depreciation and amortization 3,824,875 3,189,724
------------ ------------
Net equipment and leasehold improvements 12,099,670 12,010,521
Long-term marketable investment securities 10,901,051 15,449,360
Other assets 50,979 50,979
------------ ------------
$ 74,623,093 $ 76,063,331
============ ============
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable $ 1,731,453 $ 2,559,035
Accrued liabilities 2,441,402 1,154,254
Deferred revenue 5,424,930 5,699,427
Current portion of notes payable 351,906 342,796
------------ ------------
Total current liabilities 9,949,691 9,755,512
------------ ------------
Notes payable, less current portion 37,218 128,844
Stockholders' equity
Common stock, $0.01 par value, 15,000,000 shares authorized;
issued and outstanding 9,266,216 shares on September 30,
1997 and 9,222,552 shares on June 30, 1997 92,662 92,226
Additional paid-in capital 91,730,970 91,605,739
Fair value adjustment on available-for-sale marketable
investment securities 91 5,382
Deferred compensation (1,244,346) (1,376,980)
Accumulated deficit (25,943,193) (24,147,392)
------------ ------------
Net stockholders' equity 64,636,184 66,178,975
------------ ------------
$ 74,623,093 $ 76,063,331
============ ============
See accompanying notes to condensed consolidated financial statements.
3
MYRIAD GENETICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Three Months Ended
---------------------------------------------
Sept. 30, 1997 Sept. 30, 1996
(Unaudited) (Unaudited)
------------------- -------------------
Research revenue $ 5,515,042 $ 2,195,781
Genetic testing revenue 409,545 -
----------- ------------
Total revenues 5,924,587 2,195,781
Costs and expenses:
Research and development expenses 6,200,637 4,094,743
Selling, general and administrative expenses 2,137,228 1,759,959
Genetic testing cost of revenue 235,999 -
----------- ------------
Total costs and expenses 8,573,864 5,854,702
----------- ------------
Operating loss (2,649,277) (3,658,921)
Other income (expense):
Interest income 864,803 848,494
Interest expense (11,448) (19,652)
Other 121 -
----------- ------------
853,476 828,842
----------- ------------
Net loss ($1,795,801) ($2,830,079)
----------- ------------
Net loss per share ($0.19) ($0.32)
=========== ============
Weighted average shares outstanding 9,237,843 8,712,829
=========== ============
See accompanying notes to condensed consolidated financial statements.
4
MYRIAD GENETICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Three Months Ended
---------------------------------------------
Sept. 30, 1997 Sept. 30, 1996
(Unaudited) (Unaudited)
------------------- -------------------
Cash flows from operating activities:
Net loss ($1,795,801) ($2,830,079)
Adjustments to reconcile net loss to net cash used in
operating activities:
Depreciation and amortization 769,116 496,768
Increase in trade receivables (3,310) -
Decrease (increase) in non-trade receivables (34,696) 62,079
Decrease (increase) in prepaid expenses 289,162 (8,027)
Increase in accounts payable and accrued expenses 459,566 461,839
Increase (decrease) in deferred revenue (274,497) 244,219
------------ ------------
Net cash used in operating activities (590,460) (1,573,201)
------------ ------------
Cash flows from investing activities:
Capital expenditures (725,631) (1,615,197)
Net change in marketable investment securities 6,044,404 4,845,526
------------ ------------
Net cash provided by investing activities 5,318,773 3,230,329
------------ ------------
Cash flows from financing activities:
Net payments of notes payable (82,516) (74,186)
Net proceeds from issuance of common stock 125,667 25,958
------------ ------------
Net cash provided by (used in) financing activities 43,151 (48,228)
------------ ------------
Net increase in cash and cash equivalents 4,771,464 1,608,900
Cash and cash equivalents at beginning of period 15,675,763 13,235,680
------------ ------------
Cash and cash equivalents at end of period $ 20,447,227 $ 14,844,580
============ ============
See accompanying notes to condensed consolidated financial statements.
5
MYRIAD GENETICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(1) Basis of Presentation
---------------------
The accompanying condensed unaudited consolidated financial statements
have been prepared by Myriad Genetics, Inc. (the "Company") in
accordance with generally accepted accounting principles for interim
financial information and pursuant to the applicable rules and
regulations of the Securities and Exchange Commission. The condensed
unaudited consolidated financial statements include the accounts of
the Company and its wholly-owned subsidiaries. All material
intercompany accounts and transactions have been eliminated in
consolidation. In the opinion of management, the accompanying
financial statements contain all adjustments (consisting of normal and
recurring accruals) necessary to present fairly all financial
statements. The financial statements herein should be read in
conjunction with the Company's audited consolidated financial
statements and notes thereto for the fiscal year ended June 30, 1997,
included in the Company's Annual Report on Form 10-K for the year
ended June 30, 1997. Operating results for the three-month period
ended September 30, 1997 may not necessarily be indicative of the
results to be expected for any other interim period or for the full
year.
(2) Subsequent Event
----------------
In October 1997, the Company entered into an arrangement with Swiss
Bank Corporation, London Branch ("SBC") under which the Company
simultaneously purchased and sold call options on its own Common Stock
resulting in a payment of $100,000 to the Company. The capped call
option purchased by the Company ("Contract A") gives the Company the
right, at option expiration, to (i) purchase 400,000 shares of its own
stock at a strike price of $32.25 or (ii) receive a cash settlement in
an amount equal to the difference between the strike price and the
lesser of the market price at the exercise date or the cap price of
$40.50.
The call option sold by the Company ("Contract B") gives SBC the
right, at option expiration, to purchase 400,000 shares of newly
issued Myriad Common Stock, subject to the effectiveness of a
registration statement, at a strike price of $40.50. Alternatively,
the Company may elect to cash settle, or net share settle the option.
It is management's intent to cash settle contract A, and if the market
price exceeds $40.50 at the option expiration date, to settle Contract
B through the issuance of Myriad stock. If both contracts are
exercised, the Company may receive up to $19,500,000, or $48.75 per
share. Both call options will expire in December 1998.
SBC has advised that it has engaged, and may engage, in transactions,
including buying and selling shares of the Company's Common Stock, to
offset its risk relating to the options. Purchases and sales could
affect the market price of the Company's Common Stock.
6
MANAGEMENT'S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
OVERVIEW
Since inception, the Company has devoted substantially all of its resources to
maintaining its research and development programs, establishing and operating a
genetic testing laboratory, and supporting collaborative research agreements.
Revenues received by the Company primarily have been payments pursuant to
collaborative research agreements and sales of genetic tests. The Company has
been unprofitable since its inception and, for the quarter ended September 30,
1997, the Company had a net loss of $1,795,801 and as of September 30, 1997 had
an accumulated deficit of $25,943,193.
In April 1995, the Company commenced a five-year collaborative research and
development arrangement with Novartis Corporation ("Novartis"). This
collaboration provides the Company with an equity investment, research funding
and potential milestone payments totalling up to $60,000,000. The Company is
entitled to receive royalties from sales of therapeutic products sold by
Novartis. The Company recognized $1,323,208 in revenue under this agreement for
the quarter ended September 30, 1997.
In September 1995, the Company commenced a five-year collaborative research and
development arrangement with Bayer Corporation ("Bayer"). This collaboration
provides the Company with an equity investment, research funding and potential
milestone payments totalling up to $71,000,000. The Company is entitled to
receive royalties from sales of therapeutic products sold by Bayer. The Company
recognized $1,441,833 in revenue under this agreement for the quarter ended
September 30, 1997.
In October 1996, the Company announced the introduction of BRACAnalysis(TM), a
comprehensive BRCA1 and BRCA2 gene sequence analysis for susceptibility to
breast and ovarian cancer. The Company, through its wholly owned subsidiary
Myriad Genetic Laboratories, Inc., began accepting testing samples on a
commercial basis on October 30, 1996. Genetic testing revenues of $409,545 were
recognized for the quarter ended September 30, 1997.
In April 1997, the Company commenced a three-year collaborative research and
development arrangement with Schering Corporation ("Schering"). The three-year
term may be extended for two additional one-year periods. This collaboration
provides the Company with an equity investment, license fees, research funding
and potential milestone payments totalling up to $60,000,000. The Company is
entitled to receive royalties from sales of therapeutic products sold by
Schering. The Company recognized $750,000 in revenue under this agreement for
the quarter ended September 30, 1997.
In October 1997, the Company announced that Schering has licensed the
therapeutic rights to the MMAC1 gene. The MMAC1 gene, located through a
collaborative effort by scientists at the Company and the University of Texas
M.D. Anderson Cancer Center, has been associated with advanced cancers of the
brain, prostate, breast, kidney, and skin. The licensing of this gene triggered
a milestone payment of $2,000,000 from Schering to the Company. The Company may
receive additional drug development milestone payments and royalties on
therapeutic products based on the MMAC1 gene and its pathways. Myriad has
retained the rights and will continue development of the molecular diagnostic
potential of the MMAC1 gene.
The Company intends to enter into additional collaborative relationships to
locate and sequence genes associated with other common diseases as well as
continuing to fund internal research projects. There can be no assurance that
the Company will be able to enter into additional collaborative relationships on
terms acceptable to the Company. The Company expects to incur losses for at
least the next several years, primarily due to expansion of its research and
development programs, increased staffing costs and expansion of its facilities.
Additionally, the Company expects to incur substantial sales, marketing and
other expenses in connection with building its genetic testing business. The
Company expects that losses will fluctuate from quarter to quarter and that such
fluctuations may be substantial.
7
RESULTS OF OPERATIONS
THREE MONTHS ENDED SEPTEMBER 30, 1997 AND 1996
Research revenues for the quarter ended September 30, 1997 increased $3,319,261
from the same quarter of 1996. Research revenue from both the Novartis and Bayer
research agreements increased modestly from the first fiscal quarter of 1996.
The research revenues from the collaborative research agreement initiated with
Schering in April 1997 and Schering's milestone payment associated with the
licensing of the MMAC1 gene account for approximately 83% of the increase from
the prior year. Research revenue from the research collaboration agreements is
recognized as related costs are incurred. Consequently, as these programs
progress and costs increase, revenues increase proportionately.
Genetic testing revenues of $409,545 were recognized in the quarter ended
September 30, 1997, all of which were sales of diagnostic tests resulting from
the Company's discovery of the BRCA1 and BRCA2 breast and ovarian cancer genes.
Since these tests for genetic predisposition to breast and ovarian cancer were
launched by the Company in October 1996, there were no genetic testing revenues
for the comparable quarter ended September 30, 1996.
Research and development expenses for the quarter ended September 30, 1997
increased to $6,200,637 from $4,094,743 for the same quarter of 1996. This
increase was primarily due to an increase in research activities as a result of
the progress in the Company's collaborations with Novartis, Bayer and Schering
as well as those programs funded by the Company. The increased level of
research spending includes third party research programs, increased depreciation
charges related to purchasing additional research equipment, the hiring of
additional research personnel and the associated increase in use of laboratory
supplies and reagents. The Company also incurred expenses related to milestones
achieved by it academic collaborators. Such expenses will likely increase to
the extent that the Company enters into additional research agreements with
third parties.
Selling, general and administrative expenses for the quarter ended September 30,
1997 increased $377,269 from the same quarter of 1996. The increase was
attributable to costs associated with the ongoing promotion of BRACAnalysis(TM)
as well as additional administrative, sales, marketing and education personnel,
market research activities, education material development, and facilities-
related costs. The Company expects its selling, general and administrative
expenses will continue to increase in support of its genetic testing business
and its research and development efforts.
Interest income for the quarter ended September 30, 1997 increased $16,309 or 2%
from the same quarter of 1996. The Company has been able to maintain its cash
reserves at a relatively constant level as a result of its ongoing collaborative
research agreements, entering new collaborative agreements, achieving research
milestones, and sales of its genetic tests. As a result, interest income has
not changed significantly from the prior year. Interest expense for the quarter
ended September 30, 1997, amounting to $11,448, was due entirely to borrowings
under the Company's equipment financing facility.
LIQUIDITY AND CAPITAL RESOURCES
Net cash used in operating activities was $590,460 during the quarter ended
September 30, 1997 and $1,573,201 during the same quarter of 1996. Non-trade
receivables increased $34,696 between June 30, 1997 and September 30, 1997
primarily as a result of certain patent legal fees which the Company has
incurred and which will be reimbursed by one of the Company's collaborative
partners. Prepaid expenses decreased $289,162 during the quarter ended
September 30, 1997. The decrease is primarily due to advance royalties and
insurance premiums being expensed during the quarter. Accounts payable and
accrued expenses increased $459,566 between June 30, 1997 and September 30, 1997
primarily as a result of a milestone payment owed by the Company to one of its
academic collaborators. Deferred revenue, representing the difference in
collaborative payments received and research revenue recognized, decreased
$274,497.
The Company's investing activities provided cash of $5,318,773 in the three
months ended September 30, 1997 and $3,230,329 in the three months ended
September 30, 1996. Investing activities were comprised primarily of capital
expenditures for research equipment, office furniture, and facility improvements
and reinvestment of marketable investment securities from longer term
investments to short-term cash equivalents in order to provide for ongoing
corporate expenditures.
8
Financing activities provided $43,151 during the quarter ended September 30,
1997. The Company reduced the principal on its equipment financing facility by
$82,516. This decrease was offset by proceeds of $125,667 from the exercise of
stock options. Financing activities used $48,228 during the quarter ended
September 30, 1996. The Company reduced the principal on its equipment
financing facility by $74,186 and received proceeds from stock option exercises
of $25,958 during the 1996 quarter.
In October 1997, the Company entered into an arrangement with SBC under which
the Company simultaneously purchased and sold call options on its own Common
Stock resulting in a payment of $100,000 to the Company. The capped call option
purchased by the Company ("Contract A") gives the Company the right, at option
expiration, to (i) purchase 400,000 shares of its own stock at a strike price of
$32.25 or (ii) receive a cash settlement in an amount equal to the difference
between the strike price and the lesser of the market price at the exercise date
or the cap price of $40.50.
The call option sold by the Company ("Contract B") gives SBC the right, at
option expiration, to purchase 400,000 shares of newly issued Myriad Common
Stock, subject to the effectiveness of a registration statement, at a strike
price of $40.50. Alternatively, the Company may elect to cash settle, or net
share settle the option. It is managements intent to cash settle contract A,
and if the market price exceeds $40.50 at the option expiration date, to settle
Contract B through the issuance of Myriad stock. If both contracts are
exercised, the Company may receive up to $19,500,000 or $48.75 per share. Both
call options will expire in December 1998.
SBC has advised that it has engaged, and may engage, in transactions, including
buying and selling shares of the Company's Common Stock, to offset its risk
relating to the options. Purchases and sales could affect the market price of
the Company's Common Stock.
The Company anticipates that its existing capital resources, including the net
proceeds of its initial public offering and interest earned thereon, will be
adequate to maintain its current and planned operations for at least the next
two years, although no assurance can be given that changes will not occur that
would consume available capital resources before such time. The Company's
future capital requirements will be substantial and will depend on many factors,
including progress of the Company's research and development programs, the
results and cost of clinical correlation testing of the Company's genetic tests,
the costs of filing, prosecuting and enforcing patent claims, competing
technological and market developments, payments received under collaborative
agreements, changes in collaborative research relationships, the costs
associated with potential commercialization of its gene discoveries, if any,
including the development of manufacturing, marketing and sales capabilities,
the cost and availability of third-party financing for capital expenditures and
administrative and legal expenses. Because of the Company's significant long-
term capital requirements, the Company intends to raise funds when conditions
are favorable, even if it does not have an immediate need for additional capital
at such time.
CERTAIN FACTORS THAT MAY AFFECT FUTURE RESULTS OF OPERATIONS
The Company believes that this report on Form 10-Q contains certain forward-
looking statements as that term is defined in the Private Securities Litigation
Reform Act of 1995. Such statements are based on management's current
expectations and are subject to a number of factors and uncertainties which
could cause actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that there can be no
assurance that actual results or business conditions will not differ materially
from those projected or suggested in such forward-looking statements as a result
of various factors, including, but not limited to, the following: intense
competition related to the discovery of disease-related genes and the
possibility that others may discover, and the Company may not be able to gain
rights with respect to, genes important to the establishment and operation of a
successful genetic testing business, difficulties inherent in developing genetic
tests once genes have been discovered; the Company's limited experience in
developing and operating a genetic testing laboratory; the Company's limited
marketing and sales experience and the risk that BRACAnalysis(TM) and any other
tests which the Company develops may not be able to be marketed at acceptable
prices or receive commercial acceptance in the markets that the Company is
targeting or expects to target; uncertainty as to whether there will exist
adequate reimbursement for the Company's services from government, private
healthcare insurers and third-party payors; and uncertainties as to the
9
extent of future government regulation of the Company's business. As a result,
the Company's future development efforts involve a high degree of risk. For
further information, refer to the more specific risks and uncertainties
disclosed throughout this Quarterly Report on From 10-Q.
10
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS.
The Company is not a party to any litigation in any court, and management is not
aware of any contemplated proceeding by any governmental authority against the
Company.
ITEM 2. CHANGES IN SECURITIES.
(c) Sales of Unregistered Securities
--------------------------------
During the three months ended September 30, 1997, the Company issued a total of
43,664 shares of Common Stock to various Directors, consultants, and employees
of the Company pursuant to the exercise of stock options at a weighted average
price of $4.24 per share.
In October 1997, the Company sold to SBC a call option entitling SBC to purchase
from the Company at a strike price of $40.50 per share, an aggregate of 400,000
shares of the Company's Common Stock. In exchange, the Company purchased from
SBC a capped call option giving the Company the right to purchase from SBC up to
a total of 400,000 shares of Myriad Common Stock at a strike price of $32.25 on
a specified date. See "Management's Discussion and Analysis of Financial
Condition and Results of Operations."
No person acted as an underwriter with respect to the transactions set forth
above. In each of the foregoing instances, the Company relied on Section 4(2)
of the Securities Act of 1933, as amended (the "Securities Act") or Rule 701
promulgated under the Securities Act for the exemption from the registration
requirements of the Securities Act, since no public offerings were involved.
(d) Use of Proceeds
---------------
Pursuant to Rule 463 of the Securities Act, the Company filed its initial Form
SR with the Securities and Exchange Commission on January 15, 1996 reporting for
the period from October 5, 1995 (the effective date of the Company's
registration statement for its initial public offering) through January 5, 1996.
The Company has filed amendments to its Form SR covering each subsequent six
month period on a timely basis, the most recent of which was filed July 8, 1997
("SR Amendment No. 3") reporting for the period from January 5, 1997 through
July 5, 1997. The following schedule reflects as of September 30, 1997 an
estimate of the amount of net offering proceeds received by the Company from its
initial public offering used for each of the purposes listed below (and reflects
only the changes to the information provided by the Company in SR Amendment No.
3).
Direct or indirect payments to anyone other than
directors, officers, persons owning ten percent or
more of any class of equity securities of the Company,
and affiliates of the Company (of which there were no
such payments).
- ----------------------------------------------------------------------------------------------------------------
Construction of plant, building and facilities $ 1,394,256
- ----------------------------------------------------------------------------------------------------------------
Purchase and installation of machinery and equipment $10,341,872
- ----------------------------------------------------------------------------------------------------------------
Cash and investments $12,146,340
- ----------------------------------------------------------------------------------------------------------------
Genetic discovery research expenses $ 6,596,655
- ----------------------------------------------------------------------------------------------------------------
Diagnostic test development and operation expenses $11,440,785
- ----------------------------------------------------------------------------------------------------------------
General and administrative expenses $ 7,343,285
================================================================================================================
11
ITEM 3. DEFAULTS UPON SENIOR SECURITIES.
None.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
ITEM 5. OTHER INFORMATION.
None.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits
--------
The following is a list of exhibits filed as part of this Quarterly Report
on Form 10-Q.
Exhibit
Number Description
- ------ -----------
10.1 Standard Research Agreement between the Company and Valley Mental
Health dated September 1, 1997 (central nervous system disorders).
The Company has excluded from this Exhibit 10.1 portions of the
Standard Research Agreement for which the Company has requested
confidential treatment from the Securities and Exchange Commission.
The portions of the Standard Research Agreement for which
confidential treatment has been requested are marked " * " and such
confidential portions have been filed separately with the Securities
and Exchange Commission.
10.2 International Swap Dealers Association, Inc. Master Agreement ("ISDA
Master Agreement") between the Company and Swiss Bank Corporation,
London Branch dated October 8, 1997.
10.3 Schedule to ISDA Master Agreement between the Company and Swiss Bank
Corporation, London Branch dated October 8, 1997.
10.4 Confirmation for Contract A entered into pursuant to ISDA Master
Agreement between the Company and Swiss Bank Corporation, London
Branch dated October 22, 1997.
10.5 Confirmation for Contract B entered into pursuant to ISDA Master
Agreement between the Company and Swiss Bank Corporation, London
Branch dated October 22, 1997.
11.1 Statement Regarding Computation of Net Loss Per Share
27.1 Financial Data Schedule
(b) Reports on Form 8-K
-------------------
No reports on Form 8-K were filed during the quarter ended September 30, 1997.
12
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
MYRIAD GENETICS, INC.
Date: November 13,1997 By: /s/ Peter D. Meldrum
------------------- -------------------------------
Peter D. Meldrum
President and Chief Executive Officer
Date: November 13,1997 /s/ Jay M. Moyes
------------------- ----------------------------------
Jay M. Moyes
Vice President of Finance and Chief Financial
Officer (principal financial and accounting
officer)
13
MYRIAD GENETICS, INC.
EXHIBIT INDEX
Exhibit
Number Description
- ------ -----------
10.1 Standard Research Agreement between the Company and Valley Mental
Health dated September 1, 1997 (central nervous system disorders).
The Company has excluded from this Exhibit 10.1 portions of the
Standard Research Agreement for which the Company has requested
confidential treatment from the Securities and Exchange Commission.
The portions of the Standard Research Agreement for which
confidential treatment has been requested are marked " * " and such
confidential portions have been filed separately with the Securities
and Exchange Commission.
10.2 International Swap Dealers Association, Inc. Master Agreement ("ISDA
Master Agreement") between the Company and Swiss Bank Corporation,
London Branch dated October 8, 1997.
10.3 Schedule to ISDA Master Agreement between the Company and Swiss
Bank Corporation, London Branch dated October 8, 1997.
10.4 Confirmation for Contract A entered into pursuant to ISDA Master
Agreement between the Company and Swiss Bank Corporation, London
Branch dated October 22, 1997.
10.5 Confirmation for Contract B entered into pursuant to ISDA Master
Agreement between the Company and Swiss Bank Corporation, London
Branch dated October 22, 1997.
11.1 Statement Regarding Computation of Net Loss Per Share
27.1 Financial Data Schedule
14
EXHIBIT 10.1
MYRIAD GENETICS, INC. HAS OMITTED FROM THIS EXHIBIT 10.1 PORTIONS OF THE
AGREEMENT FOR WHICH MYRIAD GENETICS, INC. HAS REQUESTED CONFIDENTIAL TREATMENT
FROM THE SECURITIES AND EXCHANGE COMMISSION. THE PORTIONS OF THE AGREEMENT FOR
WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED ARE MARKED "*" AND SUCH
CONFIDENTIAL PORTIONS HAVE BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION.
STANDARD RESEARCH AGREEMENT
This agreement is entered into by and between Myriad Genetics, Inc., having its
address at 320 Wakara Way, Salt Lake City, UT 84108, hereinafter referred to as
the "Sponsor", and Valley Mental Health, having its address at 5965 South 900
East, Salt Lake City, Utah 84121, hereinafter referred to as "VMH". This
Agreement is dated and effective as of September 1, 1997.
Whereas, the Sponsor desires research services in accordance with the scope of
work outlined within this Agreement; and
Whereas, the performance of such research is consistent, compatible and
beneficial to the mission of VMH and, in consideration of the mutual promises
and covenants contained herein, the parties hereto agree as follows:
ARTICLE I - SCOPE OF WORK
A. VMH agrees to devote reasonable personnel and resources and efforts to
perform for the Sponsor the research activities, as described in Attachment
A, attached hereto and made a part hereof, to assist Sponsor to develop a
database of central nervous system (CNS) disorder families by linking VMH
records to Sponsor's genealogical records (the "Research Data Base") to
facilitate Sponsor's research to discover new genes for CNS diseases. This
project will be conducted under the direction and supervision of "*" as
principal investigator, and "*" as co-principal investigators. The
"Project" shall mean the research, development, and other work to develop
the Research Data Base as described in Attachment A, or otherwise performed
under this Agreement.
B. The Project shall be conducted and governed by this Agreement and by the
guidelines approved, if required, by the State of Utah's Protection of
Human Rights Review Committee ("PHRRC"), as the same may be adopted,
amended, revised, or replaced during the term of this Agreement. One of
the purposes of requiring the parties to adhere to those research
procedures is to ensure confidentiality of patient records in general, and
keeping patient identities and all similar identifiers from being divulged
to Sponsor in particular. Accordingly, the parties hereto agree to adhere
to a specific procedure which is intended to erect a wall of separation
between Sponsor and the patient names, addresses, telephone numbers, and
other personal identifying information. This procedure is attached in
detail in Attachment A.
In no event shall either party be required to make any disclosure or do anything
which the party believes may violate the privacy or other rights of any person
or may otherwise be illegal or unethical.
ARTICLE II - PROJECT PERIOD
The Project shall terminate on August 31, 2002 unless subsequent time extension,
supplement, addition, continuation or renewal is mutually agreed upon in writing
by the parties.
- -----------------
*-Confidential treatment requested as to certain portions, which portions are
omitted and filed separately with the Commission.
1
ARTICLE III - COMPENSATION
Sponsor agrees to reimburse VMH for services performed under this Agreement in
the total amount of "*" in accordance with the budget itemized in Attachment B
and to provide payment in accordance with the following schedule:
Invoices shall be submitted by VMH to Sponsor each month itemizing the work
performed and costs incurred. Payment terms will be Net 30 days.
VMH has no obligation to perform any research, development, or other work beyond
the budget set forth in Attachment B, or that would require VMH to incur costs
or expenses that would exceed payments received under this Agreement. The total
payment to VMH for a given year shall not exceed the total budget for that year
as specified in Attachment B unless Sponsor approves otherwise in writing.
ARTICLE IV - REPORTING REQUIREMENTS
VMH will provide quarterly reports on the progress of the Project and a final
report upon completion of the Project.
ARTICLE V - ROYALTIES
A. Royalty. Sponsor shall pay a "Royalty" to VMH equal to "*" of the Net
--------
Sales attributable to Licensed Products and Licensed Methods.
B. Definitions of Licensed Product, Licensed Method, Myriad Patent, and Net
------------------------------------------------------------------------
Sales. As used in this Agreement, the terms Licensed Product, Licensed
------
Method, Myriad Patent, and Net Sales shall have the following meanings:
"Licensed Product" shall mean any product, composition of matter, device,
apparatus, kit or component part thereof, or any other subject matter whose
manufacture, use or sale is covered by any claim or claims included in a Myriad
Patent in the country or jurisdiction in which such manufacture, use or sale
occurs.
"Licensed Method" shall mean any method, procedure, or process, or any other
subject matter whose practice, manufacture, use or sale is covered by any claim
or claims included in a Myriad Patent in the country or jurisdiction in which
such practice, manufacture, use or sale occurs.
"Myriad Patent" shall mean any United States or foreign patent or any United
States or foreign patent application which (1) claims any product, composition
of matter, device, apparatus, kit or component part thereof, method, procedure,
or process, or any other subject matter, whose invention or development is
attributable to the Research Results, and (2) which issues to Myriad, or which
is filed in the name of Myriad, or which is assigned to or controlled by Myriad.
A Myriad Patent shall not include any abandoned patent application, or any
expired patent, or any claims in a patent which are finally held to be invalid
or unenforceable by court of competent jurisdiction after the exhaustion of all
appeals. A foreign patent applications shall mean any patent application other
than a U.S. patent application. For example, PCT application designating any
foreign country shall be a foreign application.
- -----------------
*-Confidential treatment requested as to certain portions, which portions are
omitted and filed separately with the Commission.
2
"Net Sales" shall mean the gross revenues received by Sponsor or Sponsor's
Licensee from the sale, lease or other commercialization of Licensed Products or
in consideration of services performed using Licensed Methods. Net Sales shall
not include "*".
C. Royalty Payments. All references in this Agreement to dollars or $ shall
-----------------
mean dollars of the United States of America. All payment to VMH shall be
made in United States dollars. Sponsor shall pay VMH all Royalties due
hereunder on a calendar quarterly basis, with quarters ending on the last
days of March, June, September and December. The Royalty payment for a
given quarter shall be made within 60 days of the end of the quarter. To
the extent that the Net Sales received are in a form other than United
States dollars, the Royalty shall be based on published foreign exchange
rates (as constituted on the lat day of the applicable quarter) reasonably
designated by Sponsor and acceptable to VMH. Sponsor shall be responsible
for maintaining adequate books and records to accurately document the
Royalty payable to VMH. Sponsor shall act in good faith towards VMH to
ensure that VMH receives a full Royalty without diminution through
transactions with third parties that are not at "arms length."
D. Examinations and Audits. Upon the written request of, and at the expense
------------------------
of, VMH, Sponsor shall allow the books and records of Sponsor to be
examined and audited by VMH and its representatives (during reasonable
times, but no more frequently than once each calendar year, and with
reasonable advance notice so at to minimize interference with the business
operations of Sponsor) for the purpose of determining compliance with this
Agreement, including the Royalty obligations. In the event that any such
examination or audit shall determine that Royalties actually paid for any
period were less than 95% of the amount properly payable, Sponsor shall pay
the reasonable expenses actually incurred by VMH in connection therewith,
in addition to all previously unpaid Royalties plus interest. VMH and its
representatives shall not use or disclose to any third parties such books
and records, nor any of the specific information contained therein, except
as reasonably necessary if there is a breach of the Agreement.
ARTICLE VI - PUBLICATION AND CONFIDENTIALITY
VMH engages only in research that is compatible and consistent with, and
beneficial to, its mission and therefore significant results of research
activities must be reasonably available for publication. VMH agrees, however,
that the results obtained in the course of the research Project funded by
Sponsor may be submitted for publication only following full protection of all
intellectual property rights to the satisfaction of "*" and Sponsor's Research
Steering Committee (RSC). Full protection of intellectual property rights shall
mean taking the following action:
A. First, the proposed publication shall be provided to patent counsel of
Sponsor.
B. Next, patent counsel shall have a period of sixty (60) days to review the
publication and determine whether or not it contains confidential
information or subject matter for which patent protection should be sought.
If during such sixty (60) day period, RSC, "*" object(s) to publication either
on the grounds that confidential information or competitive information would be
disclosed, or that patent protection should be sought, Sponsor shall provide
written notice to VMH and the proposed publication will not be published;
provided, however, that in no event shall publication be delayed beyond eighteen
- -----------------
*-Confidential treatment requested as to certain portions, which portions are
omitted and filed separately with the Commission.
3
(18) months from the date of filing of an application for a "Gene Patent" (see
definition in Article IX below).
If the objection is on patent grounds, Sponsor shall have sixty (60) days after
such notice to prepare or have prepared and filed a patent application.
Notwithstanding anything in this Article VI or anything else in this Agreement
to the contrary:
C. VMH may publish any data or results obtained, created, or acquired by VMH
prior to, or outside the scope of, the Project;
D. there are no restrictions on publications of any information which is or
becomes publicly known through no fault of VMH; and
E. after 18 months from completion of the Project, there shall be not
restrictions on VMH's right to publish.
ARTICLE VII - INDEMNIFICATION
Each party hereto agrees to be responsible and assume liability for its own
wrongful or negligent acts or omissions, or those of its officers, agents, or
employees to the full extent required by law, and agrees to hold the other party
harmless from any such liability. Each party agrees to maintain reasonable
coverage for such liabilities either through commercial insurance or a
reasonable self-insurance mechanism, and the nature of such insurance coverage
or self-insurance mechanism will be reasonably disclosed to the other party.
ARTICLE VIII - COMPLIANCE WITH LAWS
Both parties agree that they will comply with all applicable federal, state, and
local laws, codes, regulations, rules, and orders.
ARTICLE IX - OWNERSHIP AND LICENSES
A. Preexisting Data. "VMH's Data" shall mean all data, technology, research,
-----------------
and intellectual property created, compiled, or acquired by VMH prior to or
outside the scope of the Project, including patient data. "Sponsor's Data"
shall mean all data, technology, research, and intellectual property created,
compiled, or acquired by Sponsor prior to or outside the scope of the
Project, including Sponsor's genealogy data base. It is contemplated that
certain of VMH's Data and certain of Sponsor's Data shall be contributed to
the Project and will be used to create the "Research Data Base." VMH's Data
shall be owned by VMH and may be used by Sponsor only in connection with the
Project and the Research Data Base. Sponsor's Data shall be owned by Sponsor
and may be used by VMH only in connection with the Project and the Research
Data Base.
B. Research Results. "Research Results" shall mean the data, results,
-----------------
discoveries, and work product created in the performance of the Project and
the copyrights, trade secrets, and other intellectual property therein. The
Research Results shall include the Research Data Base. The parties shall
jointly own the Research Results. However, such joint ownership shall not
extend to VMH's Data or Sponsor's Data. Neither party makes any warranty
with respect to the Research Results, including, without limitation, its
completeness, accuracy, quality, or
4
usefulness. Each party accept the Research Results on an "as is" basis.
C. Restrictions on Sponsor. Subject to the restrictions of the Agreement,
------------------------
Sponsor may use the Research Data Base to discover any Gene Product (as
defined below) or for any other reasonable purpose. However, Sponsor shall
not disclose or transfer the Research Data Base to any third party except for
Sponsor's corporate sponsor who must first agree in writing to abide by the
confidentiality provisions and other restriction of this Agreement. This
restriction does not apply to any of Sponsor's Data.
D. Restrictions on VMH. VMH may use the Research Data Base and other Research
--------------------
Results for any reasonable educational or research purpose or to improve
health care services to its patients. However, VMH shall not: (a) sell,
license, or furnish access to the Research Data Base, to any other person,
corporation or entity; or (b) use or authorize any other person, corporation,
or entity to use the Research Data Base or other Research Results to
discover, invent, characterize, or develop any Gene Product or to file any
application for a Gene Patent (as defined below). These Restrictions shall
not apply to information published in accordance with Article V. These
Restrictions do not apply to any of VMH's Data.
E. Definitions of Gene Products and Gene Patent. As used in this Agreement, the
---------------------------------------------
terms Gene Products and Gene Patent shall have the following meanings:
1. "Gene Product" shall mean any chemical entity, gene or gene fragment, RNA
molecule, RNA fragment, protein or protein fragment, including the nucleic
acid sequence encoding any of the foregoing, which is associated with the
medical conditions of any CNS disorder, and shall further mean an antibody
binding to a gene, gene product, RNA molecule, RNA fragment, chemical
entity, protein or protein fragment which is associated with the medical
conditions of any CNS disorder.
2. "Gene Patent" shall mean a U.S. or foreign composition of matter or method
of use patent, which discloses and claims a Gene Product.
ARTICLE X - PUBLICATION BY SPONSOR
Sponsor will not include the name of VMH or any of its facilities in any
advertising, sales promotion or other public communication without the prior
written approval of VMH's president or vice president except as and only to the
extent required by applicable law or regulation.
ARTICLE XI - TERMINATION
This project may be terminated by Sponsor upon written notice delivered to VMH
at least ninety (90) days prior to intended date of termination. By such
termination, neither party may nullify obligations already incurred for
performance or failure to perform prior to the date of termination. Payment
shall be made to VMH for all work and costs incurred prior to the date of
termination. VMH shall have the right to terminate the Project upon Sponsor's
breach of this Agreement.
ARTICLE XII - CHANGES AND AMENDMENTS
This Agreement constitutes the entire agreement between the parties. All
amendments and/or changes shall be by written instrument to be executed by the
parties hereto.
5
ARTICLE XIII - FORUM
In the event of any litigation or arbitration between the parties, such
litigation or arbitration shall be conducted exclusively within Salt Lake
County.
ARTICLE XIV - LIMITATION ON LIABILITY
Neither party shall have any liability to the other party for any indirect,
consequential or special damages. In no event shall VMH liability exceed an
amount equal to the total of all payments VMH receives under this Agreement.
In witness hereof, the parties hereto have caused this Agreement to be executed
as of the date set forth below by their duly authorized representatives.
VMH SPONSOR
By: /s/ Douglas P. Kettle By: /s/ Peter D. Meldrum
--------------------- --------------------
Name: Douglas P. Kettle Name: Peter D. Meldrum
--------------------- --------------------
Title: C.F.O. Title: President and C.E.O.
--------------------- --------------------
Date: 8/25/97 Date: 8/22/97
--------------------- --------------------
6
ATTACHMENT A - PROJECT
----------------------
GENERAL
- -------
"*"
SPECIFIC AIMS:
"*"
- -------------------
*-Confidential treatment requested for certain portions, which portions are
omitted and filed separately with the Commission.
7
ATTACHMENT B - BUDGET
---------------------
ANNUAL BUDGET FOR VALLEY MENTAL HEALTH
"*"
- -------------------
*-Confidential treatment requested for certain portions, which portions are
omitted and filed separately with the Commission.
8
EXHIBIT 10.2
(MULTICURRENCY--CROSS BORDER)
ISDA(R)
International Swap Dealers Association, Inc.
MASTER AGREEMENT
dated as of October 8, 1997
Swiss Bank Corporation, London Branch and Myriad Genetics, Inc. have entered
and/or anticipate entering into one or more transactions (each a "Transaction")
that are or will be governed by this Master Agreement, which includes the
schedule (the "Schedule"), and the documents and other confirming evidence (each
a "Confirmation") exchanged between the parties confirming those Transactions.
Accordingly, the parties agree as follows:--
1. Interpretation
(a) Definitions. The terms defined in Section 14 and in the Schedule will have
the meanings therein specified for the purpose of this Master Agreement.
(b) Inconsistency. In the event of any inconsistency between the provisions of
the Schedule and the other provisions of this Master Agreement, the Schedule
will prevail. In the event of any inconsistency between the provisions of any
Confirmation and this Master Agreement (including the Schedule), such
Confirmation will prevail for the purpose of the relevant Transaction.
(c) Single Agreement. All Transactions are entered into in reliance on the
fact that this Master Agreement and all Confirmations form a single agreement
between the parties (collectively referred to as this "Agreement"), and the
parties would not otherwise enter into any Transactions.
2. Obligations
(a) General Conditions.
(i) Each party will make each payment or delivery specified in each
Confirmation to be made by it, subject to the other provisions of this
Agreement.
(ii) Payments under this Agreement will be made on the due date for value
on that date in the place of the account specified in the relevant
Confirmation or otherwise pursuant to this Agreement, in freely
transferable funds and in the manner customary for payments in the required
currency. Where settlement is by delivery (that is, other than by
payment), such delivery will be made for receipt on the due date in the
manner customary for the relevant obligation unless otherwise specified in
the relevant Confirmation or elsewhere in this Agreement.
(iii) Each obligation of each party under Section 2(a)(i) is subject to
(1) the condition precedent that no Event of Default or Potential Event of
Default with respect to the other party has occurred and is continuing, (2)
the condition precedent that no Early Termination
Date in respect of the relevant Transaction has occurred or been
effectively designated and (3) each other applicable condition precedent
specified in this Agreement.
(b) Change of Account.. Either party may change its account for receiving a
payment or delivery by giving notice to the other party at least five Local
Business Days prior to the scheduled date for the payment or delivery to
which such change applies unless such other party gives timely notice of a
reasonable objection to such change.
(c) Netting. If on any date amounts would otherwise be payable:--
(i) in the same currency; and
(ii) in respect of the same Transaction,
by each party to the other, then, on such date, each party's obligation to make
payment of any such amount will be automatically satisfied and discharged and,
if the aggregate amount that would otherwise have been payable by one party
exceeds the aggregate amount that would otherwise have been payable by the other
party, replaced by an obligation upon the party by whom the larger aggregate
amount would have been payable to pay to the other party the excess of the
larger aggregate amount over the smaller aggregate amount.
The parties may elect in respect of two or more Transactions that a net amount
will be determined in respect of all amounts payable on the same date in the
same currency in respect of such Transactions, regardless of whether such
amounts are payable in respect of the same Transaction. The election may be made
in the Schedule or a Confirmation by specifying that subparagraph (ii) above
will not apply to the Transactions identified as being subject to the election,
together with the starting date (in which case subparagraph (ii) above will not,
or will cease to, apply to such Transactions from such date). This election may
be made separately for different groups of Transactions and will apply
separately to each pairing of Offices through which the parties make and receive
payments or deliveries.
(d) Deduction or Withholding for Tax.
(i) Gross-Up. All payments under this Agreement will be made without any
deduction or withholding for or on account of any Tax unless such deduction
or withholding is required by any applicable law, as modified by the
practice of any relevant governmental revenue authority, then in effect.
If a party is so required to deduct or withhold, then that party ("X")
will:--
(1) promptly notify the other party ("Y") of such requirement;
(2) pay to the relevant authorities the full amount required to be
deducted or withheld (including the full amount required to be
deducted or withheld from any additional amount paid by X to Y under
this Section 2(d)) promptly upon the earlier of determining that such
deduction or withholding is required or receiving notice that such
amount has been assessed against Y;
(3) promptly forward to Y an official receipt (or a certified copy),
or other documentation reasonably acceptable to Y, evidencing such
payment to such authorities; and
(4) if such Tax is an Indemnifiable Tax, pay to Y, in addition to the
payment to which Y is otherwise entitled under this Agreement, such
additional amount as is necessary to ensure that the net amount
actually received by Y (free and clear of
Indemnifiable Taxes, whether assessed against X or Y) will equal the
full amount Y would have received had no such deduction or withholding
been required. However, X will not be required to pay any additional
amount to Y to the extent that it would not be required to be paid but
for:--
(A) the failure by Y to comply with or perform any agreement
contained in Section 4(a)(i), 4(a)(iii) or 4(d); or
(B) the failure of a representation made by Y pursuant to Section
3(f) to be accurate and true unless such failure would not have
occurred but for (I) any action taken by a taxing authority, or
brought in a court of competent jurisdiction, on or after the
date on which a Transaction is entered into (regardless of
whether such action is taken or brought with respect to a party
to this Agreement) or (II) a Change in Tax Law.
(ii) Liability. If:--
(1) X is required by any applicable law, as modified by the practice
of any relevant governmental revenue authority, to make any deduction
or withholding in respect of which X would not be required to pay an
additional amount to Y under Section 2(d)(i)(4);
(2) X does not so deduct or withhold; and
(3) a liability resulting from such Tax is assessed directly against
X,
then, except to the extent Y has satisfied or then satisfies the liability
resulting from such Tax, Y will promptly pay to X the amount of such
liability (including any related liability for interest, but including any
related liability for penalties only if Y has failed to comply with or
perform any agreement contained in Section 4(a)(i), 4(a)(iii) or 4(d)).
(e) Default Interest; Other Amounts. Prior to the occurrence or effective
designation of an Early Termination Date in respect of the relevant Transaction,
a party that defaults in the performance of any payment obligation will, to the
extent permitted by law and subject to Section 6(c), be required to pay interest
(before as well as after judgment) on the overdue amount to the other party on
demand in the same currency as such overdue amount, for the period from (and
including) the original due date for payment to (but excluding) the date of
actual payment, at the Default Rate. Such interest will be calculated on the
basis of daily compounding and the actual number of days elapsed. If, prior to
the occurrence or effective designation of an Early Termination Date in respect
of the relevant Transaction, a party defaults in the performance of any
obligation required to be settled by delivery, it will compensate the other
party on demand if and to the extent provided for in the relevant Confirmation
or elsewhere in this Agreement.
3. Representations
Each party represents to the other party (which representations will be deemed
to be repeated by each party on each date on which a Transaction is entered into
and, in the case of the representations in Section 3(f), at all times until the
termination of this Agreement) that:--
(a) Basic Representations.
(i) Status. It is duly organised and validly existing under the laws of
the jurisdiction of its organisation or incorporation, and if relevant
under such laws, in good standing;
(ii) Powers. It has the power to execute this Agreement and any other
documentation relating to this Agreement to which it is a party, to deliver
this Agreement and any other documentation relating to this Agreement that
it is required by this Agreement to deliver and to perform its obligations
under this Agreement and any obligations it has under any Credit Support
Document to which it is a party and has taken all necessary action to
authorize such execution, delivery and performance;
(iii) No Violation or Conflict. Such execution, delivery and performance
do not violate or conflict with any law applicable to it, any provision of
its constitutional documents, any order or judgment of any court or other
agency of government applicable to it or any of its assets or any
contractual restriction binding on or affecting it or any of its assets;
(iv) Consents. All governmental and other consents that are required to
have been obtained by it with respect to this Agreement or any Credit
Support Document to which it is a party have been obtained and are in full
force and effect and all conditions of any such consents have been complied
with; and
(v) Obligations Binding. Its obligations under this Agreement and any
Credit Support Document to which it is a party constitute its legal, valid
and binding obligations, enforceable in accordance with their respective
terms (subject to applicable bankruptcy, reorganisation, insolvency,
moratorium or similar laws affecting creditors' rights generally and
subject, as to enforceability, to equitable principles of general
application (regardless of whether enforcement is sought in a proceeding in
equity or at law)).
(b) Absence of Certain Events. No Event of Default or Potential Event of
Default or, to its knowledge, Termination Event with respect to it has
occurred and is continuing and no such event or circumstance would occur as
a result of its entering into or performing its obligations under this
Agreement or any Credit Support Document to which it is a party.
(c) Absence of Litigation. There is not pending or, to its knowledge,
threatened against it or any of its Affiliates any action, suit or proceeding at
law or in equity or before any court, tribunal, governmental body, agency or
official or any arbitrator that is likely to affect the legality, validity or
enforceability against it of this Agreement or any Credit Support Document to
which it is a party or its ability to perform its obligations under this
Agreement or such Credit Support Document.
(d) Accuracy of Specified Information. All applicable information that is
furnished in writing by or on behalf of it to the other party and is identified
for the purpose of this Section 3(d) in the Schedule is, as of the date of the
information, true, accurate and complete in every material respect.
(e) Payer Tax Representation. Each representation specified in the Schedule as
being made by it for the purpose of this Section 3(e) is accurate and true.
(f) Payee Tax Representations. Each representation specified in the Schedule
as being made by it for the purpose of this Section 3(f) is accurate and true.
4. Agreements
Each party agrees with the other that, so long as either party has or may have
any obligation under this Agreement or under any Credit Support Document to
which it is a party:--
(a) Furnish Specified Information. It will deliver to the other party or, in
certain cases under subparagraph (iii) below, to such government or taxing
authority as the other party reasonably directs:--
(i) any forms, documents or certificates relating to taxation specified in
the Schedule or any Confirmation;
(ii) any other documents specified in the Schedule or any Confirmation;
and
(iii) upon reasonable demand by such other party, any form or document
that may be required or reasonably requested in writing in order to allow
such other party or its Credit Support Provider to make a payment under
this Agreement or any applicable Credit Support Document without any
deduction or withholding for or on account of any Tax or with such
deduction or withholding at a reduced rate (so long as the completion,
execution or submission of such form or document would not materially
prejudice the legal or commercial position of the party in receipt of such
demand), with any such form or document to be accurate and completed in a
manner reasonably satisfactory to such other party and to be executed and
to be delivered with any reasonably required certification,
in each case by the date specified in the Schedule or such Confirmation or, if
none is specified, as soon as reasonably practicable.
(b) Maintain Authorisations. It will use all reasonable efforts to maintain in
full force and effect all consents of any governmental or other authority that
are required to be obtained by it with respect to this Agreement or any Credit
Support Document to which it is a party and will use all reasonable efforts to
obtain any that may become necessary in the future.
(c) Comply with Laws. It will comply in all material respects with all
applicable laws and orders to which it may be subject if failure so to comply
would materially impair its ability to perform its obligations under this
Agreement or any Credit Support Document to which it is a party.
(d) Tax Agreement. It will give notice of any failure of a representation made
by it under Section 3(f) to be accurate and true promptly upon learning of such
failure.
(e) Payment of Stamp Tax. Subject to Section 11, it will pay any Stamp Tax
levied or imposed upon it or in respect of its execution or performance of this
Agreement by a jurisdiction in which it is incorporated, organised, managed and
controlled, or considered to have its seat, or in which a branch or office
through which it is acting for the purpose of this Agreement is located ("Stamp
Tax Jurisdiction") and will indemnify the other party against any Stamp Tax
levied or imposed upon the other party or in respect of the other party's
execution or performance of this Agreement by any such Stamp Tax Jurisdiction
which is not also a Stamp Tax Jurisdiction with respect to the other party.
5. Events of Default and Termination Events
(a) Events of Default. The occurrence at any time with respect to a party or,
if applicable, any Credit Support Provider of such party or any Specified
Entity of such party of any of the following events constitutes an event of
default (an "Event of Default") with respect to such party:--
(i) Failure to Pay or Deliver. Failure by the party to make, when due, any
payment under this Agreement or delivery under Section 2(a)(i) or 2(e)
required to be made by it if such failure is not remedied on or before the
third Local Business Day after notice of such failure is given to the
party;
(ii) Breach of Agreement. Failure by the party to comply with or perform
any agreement or obligation (other than an obligation to make any payment
under this Agreement or delivery under Section 2(a)(i) or 2(e) or to give
notice of a Termination
Event or any agreement or obligation under Section 4(a)(i), 4(a)(iii) or
4(d) to be complied with or performed by the party in accordance with this
Agreement if such failure is not remedied on or before the thirtieth day
after notice of such failure is given to the party;
(iii) Credit Support Default.
(1) Failure by the party or any Credit Support Provider of such party
to comply with or perform any agreement or obligation to be complied
with or performed by it in accordance with any Credit Support Document
if such failure is continuing after any applicable grace period has
elapsed;
(2) the expiration or termination of such Credit Support Document or
the failing or ceasing of such Credit Support Document to be in full
force and effect for the purpose of this Agreement (in either case
other than in accordance with its terms) prior to the satisfaction of
all obligations of such party under each Transaction to which such
Credit Support Document relates without the written consent of the
other party; or
(3) the party or such Credit Support Provider disaffirms, disclaims,
repudiates or rejects, in whole or in part, or challenges the validity
of, such Credit Support Document;
(iv) Misrepresentation. A representation (other than a representation
under Section 3(e) or (f)) made or repeated or deemed to have been made or
repeated by the party or any Credit Support Provider of such party in this
Agreement or any Credit Support Document proves to have been incorrect or
misleading in any material respect when made or repeated or deemed to have
been made or repeated;
(v) Default under Specified Transaction. The party, any Credit Support
Provider of such party or any applicable Specified Entity of such party (1)
defaults under a Specified Transaction and, after giving effect to any
applicable notice requirement or grace period, there occurs a liquidation
of, an acceleration of obligations under, or any early termination of,
that Specified Transaction, (2) defaults, after giving effect to any
applicable notice requirement or grace period, in making any payment or
delivery due on the last payment, delivery or exchange date of, or any
payment on early termination of, a Specified Transaction (or such default
continues for at least three Local Business Days if there is no applicable
notice requirement or grace period) or (3) disaffirms, disclaims,
repudiates or rejects, in whole or in part, a Specified Transaction (or
such action is taken by any person or entity appointed or empowered to
operate it or act on its behalf);
(vi) Cross Default. If "Cross Default" is specified in the Schedule as
applying to the party, the occurrence or existence of (1) a default, event
of default or other similar condition or event (however described) in
respect of such party, any Credit Support Provider of such party or any
applicable Specified Entity of such party under one or more agreements or
instruments relating to Specified Indebtedness of any of them (individually
or collectively) in an aggregate amount of not less than the applicable
Threshold Amount (as specified in the Schedule) which has resulted in such
Specified Indebtedness becoming, or becoming capable at such time of being
declared, due and payable under such agreements or instruments, before it
would otherwise have been due and payable or (2) a default by such party,
such Credit Support Provider or such Specified Entity (individually or
collectively) in making one or more payments on the due date thereof in an
aggregate amount of not less than the applicable Threshold Amount under
such agreements or instruments (after giving effect to any applicable
notice requirement or grace period);
(vii) Bankruptcy. The party, any Credit Support Provider of such party or
any applicable Specified Entity of such party:--
(1) is dissolved (other than pursuant to a consolidation,
amalgamation or merger); (2) becomes insolvent or is unable to pay its
debts or fails or admits in writing its inability generally to pay its
debts as they become due; (3) makes a general assignment, arrangement
or composition with or for the benefit of its creditors; (4)
institutes or has instituted against it a proceeding seeking a
judgment of insolvency or bankruptcy or any other relief under any
bankruptcy or insolvency law or other similar law affecting creditors'
rights, or a petition is presented for its winding-up or liquidation,
and, in the case of any such proceeding or petition instituted or
presented against it, such proceeding or petition (A) results in a
judgment of insolvency or bankruptcy or the entry of an order for
relief or the making of an order for its winding-up or liquidation or
(B) is not dismissed, discharged, stayed or restrained in each case
within 30 days of the institution or presentation thereof; (5) has a
resolution passed for its winding-up, official management or
liquidation (other than pursuant to a consolidation, amalgamation or
merger); (6) seeks or becomes subject to the appointment of an
administrator, provisional liquidator, conservator, receiver, trustee,
custodian or other similar official for it or for all or substantially
all its assets; (7) has a secured party take possession of all or
substantially all its assets or has a distress, execution, attachment,
sequestration or other legal process levied, enforced or sued on or
against all or substantially all its assets and such secured party
maintains possession, or any such process is not dismissed,
discharged, stayed or restrained, in each case within 30 days
thereafter; (8) causes or is subject to any event with respect to it
which, under the applicable laws of any jurisdiction, has an analogous
effect to any of the events specified in clauses (1) to (7)
(inclusive); or (9) takes any action in furtherance of, or indicating
its consent to, approval of, or acquiescence in, any of the foregoing
acts; or
(viii) Merger Without Assumption. The party or any Credit Support
Provider of such party consolidates or amalgamates with, or merges with or
into, or transfers all or substantially all its assets to, another entity
and, at the time of such consolidation, amalgamation, merger or transfer:--
(1) the resulting, surviving or transferee entity fails to assume all
the obligations of such party or such Credit Support Provider under
this Agreement or any Credit Support Document to which it or its
predecessor was a party by operation of law or pursuant to an
agreement reasonably satisfactory to the other party to this
Agreement; or
(2) the benefits of any Credit Support Document fail to extend
(without the consent of the other party) to the performance by such
resulting, surviving or transferee entity of its obligations under
this Agreement.
(b) Termination Events. The occurrence at any time with respect to a party
or, if applicable, any Credit Support Provider of such party or any Specified
Entity of such party of any event specified below constitutes an Illegality if
the event is specified in (i) below, a Tax Event if the event is specified in
(ii) below or a Tax Event Upon Merger if the event is specified in (iii) below,
and, if specified to be applicable, a Credit Event Upon Merger if the event is
specified pursuant to (iv) below or an Additional Termination Event if the event
is specified pursuant to (v) below:--
(i) Illegality. Due to the adoption of, or any change in, any applicable
law after the date on which a Transaction is entered into, or due to the
promulgation of, or any change in, the interpretation by any court,
tribunal or regulatory authority with competent
jurisdiction of any applicable law after such date, it becomes unlawful
(other than as a result of a breach by the party of Section 4(b)) for such
party (which will be the Affected Party):--
(1) to perform any absolute or contingent obligation to make a
payment or delivery or to receive a payment or delivery in respect of
such Transaction or to comply with any other material provision of
this Agreement relating to such Transaction; or
(2) to perform, or for any Credit Support Provider of such party to
perform, any contingent or other obligation which the party (or such
Credit Support Provider) has under any Credit Support Document
relating to such Transaction;
(ii) Tax Event. Due to (x) any action taken by a taxing authority, or
brought in a court of competent jurisdiction, on or after the date on which
a Transaction is entered into (regardless of whether such action is taken
or brought with respect to a party to this Agreement) or (y) a Change in
Tax Law, the party (which will be the Affected Party) will, or there is a
substantial likelihood that it will, on the next succeeding Scheduled
Payment Date (1) be required to pay to the other party an additional amount
in respect of an Indemnifiable Tax under Section 2(d)(i)(4) (except in
respect of interest under Section 2(e), 6(d)(ii) or 6(e)) or (2) receive a
payment from which an amount is required to be deducted or withheld for or
on account of a Tax (except in respect of interest under Section 2(e),
6(d)(ii) or 6(e)) and no additional amount is required to be paid in
respect of such Tax under Section 2(d)(i)(4) (other than by reason of
Section 2(d)(i)(4)(A) or (B));
(iii) Tax Event Upon Merger. The party (the "Burdened Party") on the next
succeeding Scheduled Payment Date will either (1) be required to pay an
additional amount in respect of an Indemnifiable Tax under Section
2(d)(i)(4) (except in respect of interest under Section 2(e), 6(d)(ii) or
6(e)) or (2) receive a payment from which an amount has been deducted or
withheld for or on account of any Indemnifiable Tax in respect of which the
other party is not required to pay an additional amount (other than by
reason of Section 2(d)(i)(4)(A) or (B)), in either case as a result of a
party consolidating or amalgamating with, or merging with or into, or
transferring all or substantially all its assets to, another entity (which
will be the Affected Party) where such action does not constitute an event
described in Section 5(a)(viii);
(iv) Credit Event Upon Merger. If "Credit Event Upon Merger" is
specified in the Schedule as applying to the party, such party ("X"), any
Credit Support Provider of X or any applicable Specified Entity of X
consolidates or amalgamates with, or merges with or into, or transfers all
or substantially all its assets to, another entity and such action does not
constitute an event described in Section 5(a)(viii) but the
creditworthiness of the resulting, surviving or transferee entity is
materially weaker than that of X, such Credit Support Provider or such
Specified Entity, as the case may be, immediately prior to such action
(and, in such event, X or its successor or transferee, as appropriate, will
be the Affected Party); or
(v) Additional Termination Event. If any "Additional Termination Event"
is specified in the Schedule or any Confirmation as applying, the
occurrence of such event (and, in such event, the Affected Party or
Affected Parties shall be as specified for such Additional Termination
Event in the Schedule or such Confirmation).
(c) Event of Default and Illegality. If an event or circumstance which would
otherwise constitute or give rise to an Event of Default also constitutes an
Illegality, it will be treated as an Illegality and will not constitute an Event
of Default.
6. Early Termination
(a) Right to Terminate Following Event of Default. If at any time an Event of
Default with respect to a party (the "Defaulting Party") has occurred and is
then continuing, the other party (the "Non-defaulting Party") may, by not more
than 20 days notice to the Defaulting Party specifying the relevant Event of
Default, designate a day not earlier than the day such notice is effective as an
Early Termination Date in respect of all outstanding Transactions. If, however,
"Automatic Early Termination" is specified in the Schedule as applying to a
party, then an Early Termination Date in respect of all outstanding Transactions
will occur immediately upon the occurrence with respect to such party of an
Event of Default specified in Section 5(a)(vii)(1), (3), (5), (6) or, to the
extent analogous thereto, (8), and as of the time immediately preceding the
institution of the relevant proceeding or the presentation of the relevant
petition upon the occurrence with respect to such party of an Event of Default
specified in Section 5(a)(vii)(4) or, to the extent analogous thereto, (8).
(b) Right to Terminate Following Termination Event.
(i) Notice. If a Termination Event occurs, an Affected Party will,
promptly upon becoming aware of it, notify the other party, specifying the
nature of that Termination Event and each Affected Transaction and will
also give such other information about that Termination Event as the other
party may reasonably require.
(ii) Transfer to Avoid Termination Event. If either an Illegality under
Section 5(b)(i)(1) or a Tax Event occurs and there is only one Affected
Party, or if a Tax Event Upon Merger occurs and the Burdened Party is the
Affected Party, the Affected Party will, as a condition to its right to
designate an Early Termination Date under Section 6(b)(iv), use all
reasonable efforts (which will not require such party to incur a loss,
excluding immaterial, incidental expenses) to transfer within 20 days after
it gives notice under Section 6(b)(i) all its rights and obligations under
this Agreement in respect of the Affected Transactions to another of its
Offices or Affiliates so that such Termination Event ceases to exist.
If the Affected Party is not able to make such a transfer it will give
notice to the other party to that effect within such 20 day period,
whereupon the other party may effect such a transfer within 30 days after
the notice is given under Section 6(b)(i).
Any such transfer by a party under this Section 6(b)(ii) will be subject to
and conditional upon the prior written consent of the other party, which
consent will not be withheld if such other party's policies in effect at
such time would permit it to enter into transactions with the transferee on
the terms proposed.
(iii) Two Affected Parties. If an Illegality under Section 5(b)(I)(1) or
a Tax Event occurs and there are two Affected Parties, each party will use
all reasonable efforts to reach agreement within 30 days after notice
thereof is given under Section 6(b)(i) on action to avoid that Termination
Event.
(iv) Right to Terminate. If:--
(1) a transfer under Section 6(b)(ii) or an agreement under Section
6(b)(iii), as the case may be, has not been effected with respect to
all Affected Transactions within 30 days after an Affected Party gives
notice under Section 6(b)(i); or
(2) an Illegality under Section 5(b)(i)(2), a Credit Event Upon
Merger or an Additional Termination Event occurs, or a Tax Event Upon
Merger occurs and the Burdened Party is not the Affected Party,
either party in the case of an Illegality, the Burdened Party in the case
of a Tax Event Upon Merger, any Affected Party in the case of a Tax Event
or an Additional Termination Event if there is more than one Affected
Party, or the party which is not the Affected Party in the case of a Credit
Event Upon Merger or an Additional Termination Event if there is only one
Affected Party may, by not more than 20 days notice to the other party and
provided that the relevant Termination Event is then continuing, designate
a day not earlier than the day such notice is effective as an Early
Termination Date in respect of all Affected Transactions.
(c) Effect of Designation.
(i) If notice designating an Early Termination Date is given under Section
6(a) or (b), the Early Termination Date will occur on the date so
designated, whether or nor the relevant Event of Default or Termination
Event is then continuing.
(ii) Upon the occurrence or effective designation of an Early Termination
Date, no further payments or deliveries under Section 2(a)(i) or 2(e) in
respect of the Terminated Transactions will be required to be made, but
without prejudice to the other provisions of this Agreement. The amount,
if any, payable in respect of an Early Termination Date shall be determined
pursuant to Section 6(e).
(d) Calculations.
(i) Statement.. On or as soon as reasonably practicable following the
occurrence of an Early Termination Date, each party will make the
calculations on its part, if any, contemplated by Section 6(e) and will
provide to the other party a statement (1) showing, in reasonable detail,
such calculations (including all relevant quotations and specifying any
amount payable under Section 6(e)) and (2) giving details of the relevant
account to which any amount payable to it is to be paid. In the absence of
written confirmation from the source of a quotation obtained in determining
a Market Quotation, the records of the party obtaining such quotation will
be conclusive evidence of the existence and accuracy of such quotation.
(ii) Payment Date. An amount calculated as being due in respect of any
Early Termination Date under Section 6(e) will be payable on the date that
notice of the amount payable is effective (in the case of an Early
Termination Date which is designated or occurs as a result of an Event of
Default) and on the day which is two Local Business Days after the day on
which notice of the amount payable is effective (in the case of an Early
Termination Date which is designated as a result of a Termination Event).
Such amount will be paid together with (to the extent permitted under
applicable law) interest thereon (before as well as after judgment) in the
Termination Currency, from (and including) the relevant Early Termination
Date to (but excluding) the date such amount is paid, at the Applicable
Rate. Such interest will be calculated on the basis of daily compounding
and the actual number of days elapsed.
(e) Payments on Early Termination. If an Early Termination Date occurs, the
following provisions shall apply based on the parties' election in the Schedule
of a payment measure, either "Market Quotation" or "Loss", and a payment method,
either the "First Method" or the "Second Method". If the parties fail to
designate a payment measure or payment method in the Schedule, it will be deemed
that "Market Quotation" or the "Second Method", as the case may be, shall apply.
The amount, if any, payable in respect of an Early Termination Date and
determined pursuant to this Section will be subject to any Set-off.
(i) Events of Default. If the Early Termination Date results from an Event
of Default:--
(1) First Method and Market Quotation. If the First Method and Market
Quotation apply, the Defaulting Party will pay to the Non-defaulting
Party the excess, if a positive number, of (A) the sum of the
Settlement Amount (determined by the Non-defaulting Party) in respect
of the Terminated Transactions and the Termination Currency Equivalent
of the Unpaid Amounts owing to the Non-defaulting Party over (B) the
Termination Currency Equivalent of the Unpaid Amounts owing to the
Defaulting Party.
(2) First Method and Loss. If the First Method and Loss apply, the
Defaulting Party will pay to the Non-defaulting Party, if a positive
number, the Non-defaulting Party's Loss in respect of this Agreement.
(3) Second Method and Market Quotation. If the Second Method and
Market Quotation apply, an amount will be payable equal to (A) the sum
of the Settlement Amount (determined by the Non-defaulting Party) in
respect of the Terminated Transactions and the Termination Currency
Equivalent of the Unpaid Amounts owing to the Non-defaulting Party
less (B) the Termination Currency Equivalent of the Unpaid Amounts
owing to the Defaulting Party. If that amount is a positive number,
the Defaulting Party will pay it to the Non-defaulting Party; if it is
a negative number, the Non-defaulting Party will pay the absolute
value of that amount to the Defaulting Party.
(4) Second Method and Loss. If the Second Method and Loss apply, an
amount will be payable equal to the Non-defaulting Party's Loss in
respect of this Agreement. If that amount is a positive number, the
Defaulting Party will pay it to the Non-defaulting Party; if it is a
negative number, the Non-defaulting Party will pay the absolute value
of that amount to the Defaulting Party.
(ii) Termination Events. If the Early Termination Date results from a
Termination Event: --
(1) One Affected Party. If there is one Affected Party, the amount
payable will be determined in accordance with Section 6(e)(i)(3), if
Market Quotation applies, or Section 6(e)(i)(4), if Loss applies,
except that, in either case, references to the Defaulting Party and to
the Non-defaulting Party will be deemed to be references to the
Affected Party and the party which is not the Affected Party,
respectively, and, if Loss applies and fewer than all the Transactions
are being terminated, Loss shall be calculated in respect of all
Terminated Transactions.
(2) Two Affected Parties. If there are two Affected Parties:--
(A) if Market Quotation applies, each party will determine a
Settlement Amount in respect will be payable equal to (I) the sum
of (a) one-half of the difference between the Settlement Amount
of the party with the higher Settlement Amount ("X") and the
Settlement Amount of the party with the lower Settlement Amount
("Y") and (b) the Termination Currency Equivalent of the Unpaid
Amounts owing to X less (II) the Termination Currency Equivalent
of the Unpaid Amounts owing to Y; and
(B) if Loss applies, each party will determine its Loss in
respect of this Agreement (or, if fewer than all the Transactions
are being terminated, in respect of all Terminated Transactions)
and an amount will be payable equal to one-half of the difference
between the Loss of the party with the higher
Loss ("X") and the Loss of the party with the lower Loss ("Y").
If the amount payable is a positive number, Y will pay it to X; if it
is negative number, X will pay the absolute value of that amount to Y.
(iii) Adjustment for Bankruptcy. In circumstances where an Early
Termination Date occurs because "Automatic Early Termination" applies in
respect of a party, the amount determined under this Section 6(e) will be
subject to such adjustments as are appropriate and permitted by law to
reflect any payments or deliveries made by one party to the other under
this Agreement (and retained by such other party) during the period from
the relevant Early Termination Date to the date for payment determined
under Sections 6(d)(ii).
(iv) Pre-Estimate. The parties agree that if Market Quotation applies an
amount recoverable under this Section 6(e) is a reasonable pre-estimate of
loss and not a penalty. Such amount is payable for the loss of bargain and
the loss of protection against future risks and except as otherwise
provided in this Agreement neither party will be entitled to recover any
additional damages as a consequence of such losses.
7. Transfer
Subject to Section 6(b)(ii), neither this Agreement nor any interest or
obligation in or under this Agreement may be transferred (whether by way of
security or otherwise) by either party without the prior written consent of the
other party, except that:--
(a) a party may make such a transfer of this Agreement pursuant to a
consolidation or amalgamation with, or merger with or into, or transfer of all
or substantially all its assets to, another entity (but without prejudice to any
other right or remedy under this Agreement); and
(b) a party may make such a transfer of all or any part of its interest in any
amount payable to it from a Defaulting Party under Section 6(e).
Any purported transfer that is not in compliance with this Section will be void.
8. Contractual Currency
(a) Payment in the Contractual Currency. Each payment under this Agreement
will be made in the relevant currency specified in this Agreement for that
payment (the "Contractual Currency"). To the extent permitted by applicable law,
any obligation to make payments under this Agreement in the Contractual Currency
will not be discharged or satisfied by any tender in any currency other than the
Contractual Currency, except to the extent such tender results in the actual
receipt by the party to which payment is owed, acting in a reasonable manner and
in good faith in converting the currency so tendered into the Contractual
Currency, of the full amount in the Contractual Currency of all amounts payable
in respect of this Agreement. If for any reason the amount in the Contractual
Currency so received falls short of the amount in the Contractual Currency
payable in respect of this Agreement, the party required to make the payment
will, to the extent permitted by applicable law, immediately pay such additional
amount in the Contractual Currency as may be necessary to compensate for the
shortfall. If for any reason the amount in the Contractual Currency so received
exceeds the amount in the Contractual Currency payable in respect of this
Agreement, the party receiving the payment will refund promptly the amount of
such excess.
(b) Judgments. To the extent permitted by applicable law, if any judgment or
order expressed in a currency other than the Contractual Currency is rendered
(i) for the payment of any amount owing in respect of this Agreement, (ii) for
the payment of any amount relating to any early termination in respect of this
Agreement or (iii) in respect of a judgment or order of another court
for the payment of any amount described in (i) or (ii) above, the party seeking
recovery, after recovery in full of the aggregate amount to which such party is
entitled pursuant to the judgment or order, will be entitled to receive
immediately from the other party the amount of any shortfall of the Contractual
Currency received by such party as a consequence of sums paid in such other
currency and will refund promptly to the other party any excess of the
Contractual Currency received by such party as a consequence of sums paid in
such other currency if such shortfall or such excess arises or results from any
variation between the rate of exchange at which the Contractual Currency is
converted into the currency of the judgment or order for the purposes of such
judgment or order and the rate of exchange at which such party is able, acting
in a reasonable manner and in good faith in converting the currency received
into the Contractual Currency, to purchase the Contractual Currency with the
amount of the currency of the judgment or order actually received by such party.
The term "rate of exchange" includes, without limitation, any premiums and costs
of exchange payable in connection with the purchase of or conversion into the
Contractual Currency.
(c) Separate Indemnities. To the extent permitted by applicable law, these
indemnities constitute separate and independent obligations form the other
obligations in this Agreement, will be enforceable as separate and independent
causes of action, will apply notwithstanding any indulgence granted by the party
to which any payment is owed and will not be affected by judgment being obtained
or claim or proof being made for any other sums payable in respect of this
Agreement.
(d) Evidence of Loss. For the purpose of this Section 8, it will be sufficient
for a party to demonstrate that it would have suffered a loss had an actual
exchange or purchase been made.
9. Miscellaneous
(a) Entire Agreement. This Agreement constitutes the entire agreement and
understanding of the parties with respect to its subject matter and supersedes
all oral communication and prior writings with respect thereto.
(b) Amendments. No amendment, modification or waiver in respect of this
Agreement will be effective unless in writing (including a writing evidenced by
a facsimile transmission) and executed by each of the parties or confirmed by an
exchange of telexes or electronic messages on an electronic messaging system.
(c) Survival of Obligations. Without prejudice to Sections 2(a)(iii) and
6(c)(ii), the obligations of the parties under this Agreement will survive
the termination of any Transaction.
(d) Remedies Cumulative. Except as provided in this Agreement, the rights,
powers, remedies and privileges provided in this Agreement are cumulative and
not exclusive of any rights, powers, remedies and privileges provided by law.
(e) Counterparts and Confirmations.
(i) This Agreement (and each amendment, modification and waiver in respect
of it) may be executed and delivered in counterparts (including by
facsimile transmission), each of which will be deemed an original.
(ii) The parties intend that they are legally bound by the terms of each
Transaction from the moment they agree to those terms (whether orally or
otherwise). A Confirmation shall be entered into as soon as practicable
and may be executed and delivered in counterparts (including by facsimile
transmission) or be created by an exchange of telexes or by an exchange of
electronic messages on an electronic messaging system, which in each case
will be sufficient for all purposes to evidence a binding supplement to
this Agreement. The
parties will specify therein or through another effective means that any
such counterpart, telex or electronic message constitutes a Confirmation.
(f) No Waiver of Rights. A failure or delay in exercising any right, power or
privilege in respect of this Agreement will not be presumed to operate as a
waiver, and a single or partial exercise of any right, power or privilege will
not be presumed to preclude any subsequent or further exercise, of that right,
power or privilege or the exercise of any other right, power or privilege.
(g) Headings. The headings used in this Agreement are for convenience of
reference only and are not to affect the construction of or to be taken into
consideration in interpreting this Agreement.
10. Offices; Multibranch Parties
(a) If Section 10(a) is specified in the Schedule as applying, each party that
enters into a Transaction through an Office other than its head or home office
represents to the other party that, notwithstanding the place of booking office
or jurisdiction of incorporation or organisation of such party, the obligations
of such party are the same as if it had entered into the Transaction through its
head or home office. This representation will be deemed to be repeated by such
party on each date on which a Transaction is entered into.
(b) Neither party may change the Office through which it makes and receives
payment or deliveries for the purpose of a Transaction without the prior written
consent of the other party.
(c) If a party is specified as a Multibranch Party in the Schedule, such
Multibranch Party may make and receive payments or deliveries under any
Transaction through any Office listed in the Schedule, and the Office through
which it makes and receives payments or deliveries with respect to a Transaction
will be specified in the relevant Confirmation.
11. Expenses
A Defaulting Party will, on demand, indemnify and hold harmless the other party
for and against all reasonable out-of-pocket expenses, including legal fees and
Stamp Tax, incurred by such other party by reason of the enforcement and
protection of its rights under this Agreement or any Credit Support Document to
which the Defaulting Party is a party or by reason of the early termination of
any Transaction, including, but not limited to, costs of collection.
12. Notices
(a) Effectiveness. Any notice or other communication in respect of this
Agreement may be given in any manner set forth below (except that a notice or
other communication under Section 5 or 6 may not be given by facsimile
transmission or electronic messaging system) to the address or number or in
accordance with the electronic messaging system details provided (see the
Schedule) and will be deemed effective as indicated:--
(i) if in writing and delivered in person or by courier, on the date it is
delivered;
(ii) if sent by telex, on the date the recipient's answerback is received;
(iii) if sent by facsimile transmission, on the date that transmission is
received by a responsible employee of the recipient in legible form (it
being agreed that the burden of proving receipt will be on the sender and
will not be met by a transmission report generated by the sender's
facsimile machine);
(iv) if sent by certified or registered mail (airmail, if overseas) or the
equivalent (return receipt requested), on the date that mail is delivered
or its delivery is attempted; or
(v) if sent by electronic messaging system, on the date that electronic
message is received,
unless the date of that delivery (or attempted delivery) or that receipt, as
applicable, is not a Local Business Day or that communication is delivered (or
attempted) or received, as applicable, after the close of business on a Local
Business Day, in which case that communication shall be deemed given and
effective on the first following day that is a Local Business Day.
(b) Change of Addresses. Either party may by notice to the other change the
address, telex, or facsimile number or electronic messaging system details
at which notices or other communications are to be given to it.
13. Governing Law and Jurisdiction.
(a) Governing Law. This Agreement will be governed by and construed in
accordance with the law specified in the Schedule.
(b) Jurisdiction. With respect to any suit, action or proceedings relating to
this Agreement ("Proceedings"), each party irrevocably:--
(i) submits to the jurisdiction of the English courts, if this Agreement
is expressed to be governed by English law, or to the non-exclusive
jurisdiction of the courts of the State of New York and the United States
District Court located in the Borough of Manhattan in New York City, if
this Agreement is expressed to be governed by the laws of the State of New
York; and
(ii) waives any objection which it may have at any time to the laying of
venue of any Proceedings brought in any such court, waives any claim that
such Proceedings have been brought in an inconvenient forum and further
waives the right to object, with respect to other Proceedings, that such
court does not have any jurisdiction over such party.
Nothing in this Agreement precludes either party from bringing Proceedings in
any other jurisdiction (outside, if this Agreement is expressed to be governed
by English law, the Contracting States, as defined in Section 1(3) of the Civil
Jurisdiction and Judgments Act 1982 or any modification, extension or re-
enactment thereof for the time being in force) nor will the bringing of
Proceedings in any one or mor jurisdictions preclude the bringing of Proceedings
in any other jurisdiction.
(c) Service of Process. Each party irrevocably appoints the Process Agent (if
any) specified opposite its name in the Schedule to receive, for it and on its
behalf, service of process in any Proceedings. If for any reason any party's
Process Agent is unable to act as such, such party will promptly notify the
other party and within 30 days appoint a substitute process agent to the other
party. The parties irrevocably consent to service of process given in the manner
provided for notices in Section 12. Nothing in this Agreement will affect the
right of either party to serve process in any other manner permitted by law.
(d) Waiver of Immunities. Each party irrevocably waives, to the fullest extent
permitted by applicable law, with respect to itself and its revenues and assets
(irrespective of their use or intended use), all immunity on the grounds of
sovereignty or other similar grounds from (i) suit, (ii) jurisdiction of any
court, (iii) relief by way of injunction, order for specific performance or for
recovery of property, (iv) attachments of its assets (whether before or after
judgment) and (v)
execution or enforcement of any judgment to which it or its revenues or assets
might otherwise be entitled in any Proceedings in the courts of any jurisdiction
and irrevocably agrees, to the extent permitted by applicable law, that it will
not claim any such immunity in any Proceedings.
14. Definitions
As used in this Agreement.
"Additional Termination Event" has the meaning specified in Section 5(b).
"Affected Party" has the meaning specified in Section 5(b).
"Affected Transactions" means (a) with respect to any Termination Event
consisting of an Illegality, Tax Event or Tax Event Upon Merger, all
Transactions affected by the occurrence of such Termination Event and (b) with
respect to any other Termination Event, all Transactions.
"Affiliate" means, subject to the Schedule, in relation to any person, any
entity controlled, directly or indirectly, by the person, any entity that
controls, directly or indirectly, the person or any entity directly or
indirectly under common control with the person. For this purpose, "control" of
any entity or person means ownership of a majority of the voting power of the
entity or person.
"Applicable Rate" means: --
(a) in respect of obligations payable or deliverable (or which would have been
but for Section 2(a)(iii)) by a Defaulting Party, the Default Rate;
(b) in respect of an obligation to pay an amount under Section 6(e) of either
party from and after the date (determined in accordance with Section 6(d)(ii))
on which that amount is payable, the Default Rate;
(c) in respect of all other obligations payable or deliverable (or which would
have been but for Section 2(a)(iii)) by a Non-defaulting Party, the Non-
defaulting Rate; and
(d) in all other cases, the Terminating Rate.
"Burdened Party" has the meaning specified in Section 5(b).
"Change in Tax Law" means the enactment, promulgation, execution or
ratification of, or any change in or amendment to, any law (or in the
application or official interpretation of any law) that occurs on or after the
date on which the relevant Transaction is entered into.
"Consent" includes a consent, approval, action, authorisation, exemption,
notice, filing, registration or exchange control consent.
"Credit Event Upon Merger" has the meaning specified in Section 5(b).
"Credit Support Document" means any agreement or instrument that is specified
as such in this Agreement.
"Credit Support Provider" has the meaning specified in the Schedule.
"Default Rate" means a rate per annum equal to the cost (without proof or
evidence of any actual cost) to the relevant payee (as certified by it) if it
were to fund or of funding the relevant amount plus 1% per annum.
"Defaulting Party" has the meaning specified in Section 6(a).
"Early Termination Date" means the date determined in accordance with Section
6(a) or 6(b)(iv).
"Event of Default" has the meaning specified in Section 5(a) and, if
applicable, in the Schedule.
"Illegality" has the meaning specified in Section 5(b).
"Indemnifiable Tax" means any Tax other than a Tax that would not be imposed
in respect of a payment under this Agreement but for a present or former
connection between the jurisdiction of the government or taxation authority
imposing such Tax and the recipient of such payment or a person related to such
recipient (including, without limitation, a connection arising from such
recipient or related person being or having been a citizen or resident of such
jurisdiction, or being or having been organised, present or engaged in a trade
or business in such jurisdiction, or having or having had a permanent
establishment or fixed place of business in such jurisdiction, but excluding a
connection arising solely from such recipient or related person having executed,
delivered, performed its obligations or received a payment under, or enforced,
this Agreement or a Credit Support Document).
"Law" includes any treaty, law, rule or regulation (as modified, in the case of
tax matters, by the practice of any relevant governmental revenue authority) and
"lawful" and "unlawful" will be construed accordingly.
"Local Business Day" means, subject to the Schedule, a day on which commercial
banks are open for business (including dealings in foreign exchange and foreign
currency deposits) (a) in relation to any obligation under Section 2(a)(i), in
the place(s) specified in the relevant Confirmation or, if not so specified, as
otherwise agreed by the parties in writing or determined pursuant to provisions
contained, or incorporated by reference, in this Agreement, (b) in relation to
any other payment, in the place where the relevant account is located and, if
different, in the principal financial centre, if any, of the currency of such
payment, (c) in relation to any notice or other communication, including notice
contemplated under Section 5(a)(i), in the city specified in the address for
notice provided by the recipient and, in the case of a notice contemplated by
Section 2(b), in the place where the relevant new account is to be located and
(d) in relation to Section 5(a)(v)(2), in the relevant locations for performance
with respect to such Specified Transaction.
"Loss" means, with respect to this Agreement or one or more Terminated
Transactions, as the case may be, and a party, the Termination Currency
Equivalent of an amount that party reasonably determines in good faith to be its
total losses and costs (or gain, in which case expressed as a negative number)
in connection with this Agreement or that Terminated Transaction or group of
Terminated Transactions, as the case may be, including any loss of bargain, cost
of funding or, at the election of such party but without duplication, loss or
cost incurred as a result of its terminating, liquidating, obtaining or
reestablishing any hedge or related trading position (or any gain resulting from
any of them). Loss includes losses and costs (or gains) in respect of any
payment or delivery required to have been made (assuming satisfaction of each
applicable condition precedent) on or before the relevant Early Termination Date
and not made, except, so as to avoid duplication, if Section 6(e)(i)(1) or (3)
or 6(e)(ii)(2)(A) applies. Loss does not include a party's legal fees and out-
of-pocket expenses referred to under Section 11. A party will determine its
Loss as of the relevant Early Termination Date, or, if that is not reasonably
practicable, as of the earliest date thereafter as is reasonably practicable. A
party may (but need not) determine its Loss by reference to quotations of
relevant rates or prices from one or more leading dealers in the relevant
markets.
"Market Quotation" means, with respect to one or more Terminated Transactions
and a party
making the determination, an amount determined on the basis of quotations from
Reference Market-makers. Each quotation will be for an amount, if any, that
would be paid to such party (expressed as a negative number) or by such party
(expressed as a positive number) in consideration of an agreement between such
party (taking into account any existing Credit Support Document with respect to
the obligations of such party) and the quoting Reference Market-maker to enter
into a transaction (the "Replacement Transaction") that would have the effect of
preserving for such party the economic equivalent of any payment or delivery
(whether the underlying obligation was absolute or contingent and assuming the
satisfaction of each applicable condition precedent) by the parties under
Section 2(a)(i) in respect of such Terminated Transaction or group of Terminated
Transactions that would, but for the occurrence of the relevant Early
Termination Date, have been required after that date. For this purpose, Unpaid
Amounts in respect of the Terminated Transaction or group of Terminated
Transactions are to be excluded but, without limitation, any payment or delivery
that would, but for the relevant Early Termination Date, have been required
(assuming satisfaction of each applicable condition precedent) after that Early
Termination Date is to be included. The Replacement Transaction would be subject
to such documentation as such party and the Reference Market-maker may, in good
faith, agree. The party making the determination (or its agent) will request
each Reference Market-maker to provide its quotation to the extent reasonably
practicable as of the same day and time (without regard to different time zones)
on or as soon as reasonably practicable after the relevant Early Termination
Date. The day and time as of which those quotations are to be obtained will be
selected in good faith by the party obliged to make a determination under
Section 6(e), and, if each party is so obliged, after consultation with the
other. If more than three quotations are provided, the Market Quotation will be
the arithmetic mean of the quotations, without regard to the quotations having
the highest and lowest values. If exactly three such quotations are provided,
the Market Quotation will be the quotation remaining after disregarding the
highest and lowest quotations. For this purpose, if more than one quotation has
the same highest value or lowest value, then one of such quotations shall be
disregarded. If fewer than three quotations are provided, it will be deemed that
the Market Quotation in respect of such Terminated Transaction or group of
Terminated Transactions cannot be determined.
"Non-default Rate" means a rate per annum equal to the cost (without proof or
evidence of any actual cost) to the Non-defaulting Party (as certified by it) if
it were to fund the relevant amount.
"Non-defaulting Party" has the meaning specified in Section 6(a).
"Office" means a branch or office of a party, which may be such party's head or
home office.
"Potential Event of Default" means any event which, with the giving of notice
or the lapse of time or both, would constitute an Event of Default.
"Reference Market-makers" means four leading dealers in the relevant market
selected by the party determining a Market Quotation in good faith (a) from
among dealers of the highest credit standing which satisfy all the criteria that
such party applies generally at the time in deciding whether to offer or to make
an extension of credit and (b) to the extent practicable, from among such
dealers having an office in the same city.
"Relevant Jurisdiction" means, with respect to a party, the jurisdictions (a)
in which the party is incorporated, organised, managed and controlled or
considered to have its seat, (b) where an Office through which the party is
acting for purposes of this Agreement is located, (c) in which the party
executes this Agreement and (d) in relation to any payment, from or through
which such payment is made.
"Scheduled Payment Date" means a date on which a payment or delivery is to be
made under Section 2(a)(i) with respect to a Transaction.
"Set-off" means set-off, offset, combination of accounts, right of retention or
withholding or similar right or requirement to which the payer of an amount
under Section 6 is entitled or subject (whether arising under this Agreement,
another contract, applicable law or otherwise) that is exercised by, or imposed
on, such payer.
"Settlement Amount" means, with respect to a party and any Early Termination
Date, the sum of:--
(a) the Termination Currency Equivalent of the Market Quotations (whether
positive or negative) for each Terminated Transaction or group of Terminated
Transactions for which a Market Quotation is determined; and
(b) such party's Loss (whether positive or negative and without reference to
any Unpaid Amounts) for each Terminated Transaction or group of Terminated
Transactions for which a market Quotation cannot be determined or would not
(in the reasonable belief of the party making the determination) produce a
commercially reasonable result.
"Specified Entity" has the meaning specified in the Schedule.
"Specified Indebtedness" means, subject to the Schedule, any obligation
(whether present or future, contingent or otherwise, as principal or surety or
otherwise) in respect of borrowed money.
"Specified Transaction" means, subject to the Schedule, (a) any transaction
(including an agreement with respect thereto) now existing or hereafter entered
into between one party to this Agreement (or any Credit Support Provider of such
party or any applicable Specified Entity of such party) and the other party to
this Agreement (or any Credit Support Provider of such other party or any
applicable Specified Entity of such other party) which is a rate swap
transaction, basis swap, forward rate transaction, commodity swap, commodity
option, equity or equity index swap, equity or equity index option, bond option,
interest rate option, foreign exchange transaction, cap transaction, floor
transaction, collar transaction, currency swap transaction, cross-currency rate
swap transaction, currency option or any other similar transaction (including
any option with respect to any of these transactions), (b) any combination of
these transactions and (c) any other transaction identified as a Specified
Transaction in this Agreement or the relevant confirmation.
"Stamp Tax" means any stamp, registration, documentation or similar tax.
"Tax" means any present or future tax, levy, impost, duty, charge, assessment
or fee of any nature (including interest, penalties and additions thereto) that
is imposed by any government or other taxing authority in respect of any payment
under this Agreement other than a stamp, registration, documentation or similar
tax.
"Tax Event" has the meaning specified in Section 5(b).
"Tax Event Upon Merger" has the meaning specified in Section 5(b).
"Terminated Transactions" means with respect to any Early Termination Date (a)
if resulting from a Termination Event, all Affected Transactions and (b) if
resulting from an Event of Default, all Transactions (in either case) in effect
immediately before the effectiveness of the notice designating that Early
Termination Date (or, if "Automatic Early Termination" applies, immediately
before that Early Termination Date).
"Termination Currency" has the meaning specified in the Schedule.
"Termination Currency Equivalent" means, in respect of any amount denominated
in the Termination Currency, such Termination Currency amount and, in respect
of any amount denominated in a currency other than the Termination Currency (the
"Other Currency"), the amount in the Termination Currency determined by the
party making the relevant determination as being required to purchase such
amount of such Other Currency as at the relevant Early Termination Date, or, if
the relevant Market Quotation or Loss (as the case may be), is determined as of
a later date, that later date, with the Termination Currency at the rate equal
to the spot exchange rate of the foreign exchange agent (selected as provided
below) for the purchase of such Other Currency with the Termination Currency at
or about 11:00 a.m. (in the city in which such foreign exchange agent is
located) on such date as would be customary for the determination of such a rate
for the purchase of such Other Currency for value on the relevant Early
Termination Date or that later date. The foreign exchange agent will, if only
one party is obliged to make a determination under Section 6(e), be selected in
good faith by that party and otherwise will be agreed by the parties.
"Termination Event" means an Illegality, a Tax Event or a Tax Event Upon Merger
or, if specified to be applicable, a Credit Event Upon Merger or an Additional
Termination Event.
"Termination Rate" means a rate per annum equal to the arithmetic mean of the
cost (without proof or evidence of any actual cost) to each party (as certified
by such party) if it were to fund or of funding such amounts.
"Unpaid Amounts" owing to any party means, with respect to an Early Termination
Date, the aggregate of (a) in respect of all Terminated Transactions, the
amounts that became payable (or that would have become payable but for Section
2(a)(iii) to such party under Section 2(a)(i) on or prior to such Early
Termination Date and which remain unpaid as at such Early Termination Date and
(b) in respect of each Terminated Transaction, for each obligation under Section
2(a)(i) which was (or would have been but for Section 2(a)(iii)) required to be
settled by delivery to such party on or prior to such Early Termination Date and
which has not been so settled as at such Early Termination Date, an amount equal
to the fair market value of that which was (or would have been) required to be
delivered as of the originally scheduled date for delivery, in each case
together with (to the extent permitted under applicable law) interest, in the
currency of such amounts, from (and including) the date such amounts or
obligations were or would have been required to have been paid or performed to
(but excluding) such Early Termination Date, at the Applicable Rate. Such
amounts of interest will be calculated on the basis of daily compounding and the
actual number of days elapsed. The fair market value of any obligation referred
to in clause (b) above shall be reasonably determined by the party obliged to
make the determination under Section 6(e) or, if each party is so obliged, it
shall be the average of the Termination Currency Equivalents of the fair market
values reasonably determined by both parties.
IN WITNESS WHEREOF the parties have executed this document on the respective
dates specified below with effect from the date specified on the first page of
this document.
SWISS BANK CORPORATION, MYRIAD GENETICS, INC.
LONDON BRANCH
By: /s/ Bernd E. Kallmeyer By: /s/ Jay M. Moyes
---------------------- ------------------------------
Name: Bernd E. Kallmeyer Name: Jay M. Moyes
Title: Attorney-In-Fact Title: C.F.O.
Date: October 8, 1997 Date: 10/8/97
By: /s/ Amelia Sicilia
-------------------------------
Name: Amelia Sicilia
Title: Attorney-In-Fact
Date: 10/8/97
EXHIBIT I
AGREEMENT REGARDING
REGISTRATION RIGHTS AND RELATED OBLIGATIONS
This Agreement Regarding Registration Rights and Related Obligations (this
"Agreement") is entered into this __th day of ________, 199 , between Myriad
Genetics, Inc., a Delaware corporation (the "Company"), and Swiss Bank
Corporation, a Swiss banking corporation, acting by and through its London
Branch ("SBC").
WHEREAS, on _______________ ___, 1997, the Company issued to SBC, and SBC
acquired from the Company, the Call Warrant, as defined in Section 1.2 hereof,
in consideration of a capped call option issued on that date by SBC to the
Company, as well as the other undertakings and obligations of the Company set
forth in the Call Warrant; and
WHEREAS, pursuant to the terms and conditions of the Call Warrant, if the
Call Warrant is In-the-Money (as defined in the Call Warrant), the Company has
the obligation, at its election, either (i) to sell to SBC, at the exercise
price provided for in the Call Warrant, the number of shares of the Company's
common stock, par value $01 per share (the "Common Stock"), underlying the Call
Warrant ("Physical Settlement") or (ii) to pay to SBC an amount of cash
calculated as provided in the Call Warrant ("Cash Settlement"), or (iii) to
deliver to SBC a number of shares of Common Stock having a value equal to the
Cash Settlement value ("Net Share Settlement"); and
WHEREAS, pursuant to the terms and conditions of the Call Warrant, in the
event the Company elects to discharge its obligations thereunder by Physical
Settlement or Net Share Settlement, the Company and SBC shall enter into this
Agreement; and
WHEREAS, the Company has elected to discharge its obligations under the
Call Warrant thereunder by Physical Settlement;
NOW, THEREFORE, in consideration of the foregoing and other good and
valuable consideration, the Company and SBC hereby agree as follows:
ARTICLE I DEFINITIONS
For purposes of this Agreement, the following terms shall have the
following meanings:
1.1 Call Warrant. "Call Warrant" shall mean the warrant to purchase
------------
Common Stock issued by the Company to SBC pursuant to the terms and conditions
of the Confirmation.
1.2 Commission. "Commission" shall mean the United States Securities and
----------
Exchange Commission or any successor agency thereto.
1.3 Confirmation. "Confirmation" shall mean the confirmation setting
------------
forth the terms of the Call Warrant, together with the Master Agreement
incorporated therein, dated as of _______________ ___, 1997 between the parties
hereto.
1.4 Exchange Act. "Exchange Act" shall mean the United States Securities
------------
Exchange Act of 1934, as amended.
1.5 Initial Date. "Initial Date" shall mean the date set forth in the
------------
Confirmation.
1.6 Local Business Day. "Local Business Day" shall mean a day on which
------------------
commercial banks are open for business (including dealings in foreign exchange
and foreign currency deposits) in New York, New York and Salt Lake City, Utah.
1.7 Preliminary Prospectus. "Preliminary Prospectus" shall mean any
----------------------
preliminary prospectus, including all documents incorporated by reference
therein, included in the Registration Statement or filed with the Commission
pursuant to Rule 424(a) of the rules and regulations of the Commission under the
Securities Act; any reference to any amendment or supplement to the Preliminary
Prospectus shall be deemed to include any documents filed under the Exchange Act
after the date of such Preliminary Prospectus and incorporated by reference
therein; and any reference to the Preliminary Prospectus as amended or
supplemented shall be deemed to include the Preliminary Prospectus as amended or
supplemented by any such documents filed under the Exchange Act after the date
of such Preliminary Prospectus and incorporated by reference therein.
1.8 Prospectus. "Prospectus" shall mean any prospectus, including all
----------
documents incorporated by reference therein, (i) included in the Registration
Statement as of the time that the Registration Statement is declared effective
or (ii) filed with the Commission in connection with the Registration Statement
pursuant to Rule 424(b) of the rules and regulations of the Commission under the
Securities Act; any reference to any amendment or supplement to the Prospectus
shall be deemed to include any documents filed under the Exchange Act after the
date of such Prospectus and incorporated by reference therein; and any reference
to the Prospectus as amended or supplemented shall be deemed to include the
Prospectus as amended or supplemented by any such documents filed under the
Exchange Act after the date of such Prospectus and incorporated by reference
therein.
1.9 Registration Statement. "Registration Statement" shall mean a
----------------------
registration statement on Form S-3 (or any applicable successor form then in
effect; provided that if, at the time a registration statement is to be filed,
the Company is not eligible to use Form S-3 or applicable successor form for a
primary offering by or on behalf of the Company, "Registration Statement" shall
mean a registration statement
on such form as is then available to the Company), which is to be filed with the
Commission pursuant to Section 4.1 hereof, covering the resale of the Shares
from time to time, including all exhibits thereto and all documents incorporated
by reference in the Prospectus contained in such Registration Statement at the
time it is declared effective, each as amended at the time the Registration
Statement is declared effective.
1.10 Securities Act. "Securities Act" shall mean the United States
--------------
Securities Act of 1933, as amended.
1.11 Shares. "Shares" shall mean the shares of Common Stock issuable upon
------
exercise of the Call Warrant.
1.12 Termination Date. "Termination Date" shall mean 30 Exchange Business
----------------
Days after the Maturity Date, as both such terms are defined in the
Confirmation.
ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY
The Company represents and warrants to SBC that the following are true and
correct as of the date hereof and as of the "Settlement Date" (as that term is
defined in the Confirmation):
2.1 Organization and Existence of the Company. The Company has been duly
-----------------------------------------
incorporated and is validly existing as a corporation in good standing under the
laws of the State of Delaware, with power and authority (corporate and other) to
own its properties and conduct its business as described in the 1934 Act
Reports, and has been duly qualified as a foreign corporation for the
transaction of business and is in good standing under the laws of each other
jurisdiction in which the ownership or leasing of properties, or the conduct of
its business requires such qualification, except to the extent the failure to be
so qualified would not have a material adverse effect on the Company and its
subsidiaries taken as a whole; and each subsidiary of the Company has been duly
incorporated and is validly existing as a corporation and is in good standing
under the laws of its jurisdiction of incorporation, except where the failure to
be so would not have a material adverse effect on the Company and the
subsidiaries taken as a whole.
2.2 Authorization of Transactions and Agreement. The execution, delivery
-------------------------------------------
and performance of this Agreement have been duly authorized by the board of
directors of the Company. Assuming the due execution thereof by SBC, this
Agreement constitutes the legal, valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms (except as such
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium or other laws of general application relating to or
affecting enforcement of creditors' rights and the application of equitable
principles in any action, legal or equitable, and except as rights to indemnity
or contribution may be limited by
applicable law). The Company has the corporate power to execute and deliver this
Agreement and to consummate the transactions contemplated herein.
2.3 Capitalization. (a) As of ________, 199__, the authorized capital
--------------
stock of the Company consists of (i) ___________ shares of Common Stock and (ii)
_________ shares of preferred stock, par value $___ per share (the "Preferred
Stock"), of which [specify series of preferred stock]. As of _______, 199 ,
______________ shares of Common Stock and _________ shares of Preferred Stock
were issued and outstanding, and ____________ shares of Common Stock were
reserved for issuance upon exercise of outstanding stock options and [specify
other reserved shares].
(b) The outstanding shares of Common Stock have been duly and validly
authorized and issued and are fully paid and non-assessable. The Company's
stockholders have no preemptive rights with respect to the Shares. All of the
issued shares of capital stock of each subsidiary of the Company that is a
"significant subsidiary" (as defined in Rule 12b-2 under the Exchange Act) have
been duly and validly authorized and issued, are fully paid and non-assessable
and all such shares that are owned directly or indirectly by the Company are
free and clear of all liens, encumbrances, equities or claims, with such
exceptions as would not have a material adverse effect on the Company's
ownership interest in a significant subsidiary.
(c) The Shares have been duly authorized and, when issued upon exercise of
the Call Warrant in accordance with the terms and conditions thereof, will be
validly issued, fully paid and nonassessable.
2.4 SEC Filings and Financial Statements. (a) The Company has heretofore
------------------------------------
delivered to SBC copies of the Company's (i) Annual Report on Form 10-K for the
fiscal year ended [then most recently ended fiscal year], and (ii) the proxy
statement for its 199 Annual Meeting of Stockholders, in each case,
substantially in the form filed by the Company with the Commission
(collectively, together with any other reports filed, as of the date of this
Agreement, by the Company under the Exchange Act and the rules and regulations
of the Commission since [two years before date in clause (i)] (the "1934 Act
Reports"). All of the 1934 Act Reports have complied in all material respects,
as of their respective filing dates, with all applicable requirements of the
Exchange Act and the related rules and regulations thereunder. As of their
respective filing dates, none of the 1934 Act Reports contained any untrue
statement of a material fact or omitted to state a material fact required to be
stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading. Any amending,
correcting or superseding statement made in any subsequent 1934 Act Report shall
be effective for this purpose only with respect to the period after the filing
of such subsequent 1934 Act Report.
(b) The audited consolidated financial statements and unaudited interim
financial statements of the Company contained or incorporated by reference in
the Company's 1934 Act Reports have been prepared in accordance with generally
accepted accounting principles applied on a consistent basis and, together with
the notes thereto, present fairly the consolidated financial position of the
Company and its subsidiaries at the dates shown and the consolidated results of
their operations, changes in stockholders' equity and cash flows for the periods
then ended.
2.5 No Material Adverse Change. Neither the Company nor any of its
--------------------------
subsidiaries has sustained since the date of the latest audited financial
statements included or incorporated by reference in the 1934 Act Reports any
material loss or interference with its business from fire, explosion, flood or
other calamity, whether or not covered by insurance, or from any labor dispute
or court or governmental action, order or decree, otherwise than as set forth or
contemplated in the 1934 Act Reports. Since the date of the latest audited
financial statements included or incorporated by reference in the 1934 Act
Reports, and except as may be set forth or contemplated in the 1934 Act Reports,
there has not been (i) any material change in the capital stock of the Company
(other than a change solely attributable to, or resulting from, the issuance of
Common Stock pursuant to a director, officer or employee stock option, benefit
or compensation plan), (ii) any material increase in the long-term consolidated
debt of the Company and its consolidated subsidiaries on a consolidated basis or
(iii) any material adverse change, or any development involving a prospective
material adverse change, in the general affairs, management, financial position,
stockholders' equity or results of operations of the Company and its
subsidiaries, taken as a whole, that could reasonably be expected to require
disclosure in a primary public offering of the Common Stock by the Company under
the Securities Act.
2.6 No Conflicts. The execution and delivery of this Agreement and the
------------
consummation of the transactions herein contemplated will not conflict with or
result in a breach or violation of any of the terms or provisions of, or
constitute a default under, any indenture, mortgage, deed of trust,
sale/leaseback agreement, loan agreement, similar financing agreement or
instrument or other agreement or instrument to which the Company or any of its
significant subsidiaries is a party or by which the Company or any of its
significant subsidiaries is bound or to which any of the property or assets of
the Company or any of its significant subsidiaries is subject, except for such
conflicts, breaches or violations as would not have a material adverse effect on
the Company and its subsidiaries taken as a whole or on the transactions
contemplated by this Agreement or the Confirmation; nor will such actions result
in any violation of the provisions of the Certificate of Incorporation or by-
laws of the Company or any statute applicable to the Company or any of its
significant subsidiaries or any order, judgment, decree, rule or regulation
applicable to the Company or any of its significant subsidiaries of any court or
governmental agency or body having jurisdiction over the Company or any of its
significant subsidiaries or any of their properties; and no consent, approval,
authorization, order, registration or qualification of or with any such court or
governmental agency or body is required for the consummation by the Company of
the transactions contemplated by this Agreement, except such as may be required
under the Securities Act prior to the resale of Shares and any such consents,
approvals, authorizations, registrations or qualifications as may be required
under state securities or Blue Sky laws in connection with the resale of Shares.
2.7 Litigation. Other than as set forth or contemplated in the 1934 Act
----------
Reports, there are no legal or governmental proceedings pending to which the
Company or any of its subsidiaries is a party or of which any property of the
Company or any of its subsidiaries is the subject which, if determined adversely
to the Company or any of its subsidiaries, would individually or in the
aggregate have a material adverse effect on the consolidated financial position,
stockholders' equity or results of operations of the Company and its
subsidiaries; and to the Company's knowledge, no such proceedings are threatened
or contemplated by governmental authorities or threatened by others.
2.8 Independence of Public Accountants. KPMG Peat Marwick LLP, who have
----------------------------------
audited certain financial statements of the Company and its consolidated
subsidiaries, are independent public accountants as required by the Securities
Act and the Exchange Act and the rules and regulations of the Commission
thereunder.
2.9 Not an Investment Company. The Company is not subject to regulation
-------------------------
under the Investment Company Act of 1940, as amended.
2.10 No Registration Rights. Except as provided herein or in the
----------------------
agreements listed on Schedule 2.11 hereof, no person has any right to request or
demand to have any shares of Common Stock or other securities of the Company
registered pursuant to the Registration Statement or another registration
statement pursuant to the Securities Act.
2.11 Registrant's Requirements for Form S-3. The Company meets the
--------------------------------------
registrant requirements of General Instruction I.A. of Form S-3 under the
Securities Act, as in effect on the date of this Agreement.
ARTICLE III REPRESENTATIONS AND WARRANTIES OF SBC
SBC represents and warrants to the Company that the following are true and
correct as of the date hereof and as of the Settlement Date:
3.1 Organization and Existence of SBC. SBC is a banking corporation
---------------------------------
organized under the laws of Switzerland, with power and authority (corporate and
other) to own its properties and conduct its business.
3.2 Authorization of Transactions and Agreement. The execution, delivery
-------------------------------------------
and performance of this Agreement have been duly authorized by SBC. Assuming
the due execution thereof by the Company, this Agreement constitutes the legal,
valid and binding obligation of SBC, enforceable against SBC in accordance with
its terms (except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other laws of general
application relating to or affecting enforcement of creditors' rights and the
application of equitable principles in any
action, legal or equitable, and except as rights to indemnity or contribution
may be limited by applicable law). SBC has the corporate power to execute and
deliver this Agreement and to consummate the transactions contemplated herein.
3.3 No Conflicts. The execution and delivery of this Agreement and the
------------
consummation of the transactions herein contemplated will not conflict with or
result in a breach or violation of any of the terms or provisions of, or
constitute a default under, any agreement or instrument to which SBC is a party
or by which SBC is bound or to which any of the property or assets of SBC is
subject, nor will such action result in any violation of the charter or by-laws
of SBC or any statute or any order, judgment, decree, rule or regulation of any
court or governmental agency or body having jurisdiction over SBC or any of its
properties except for such conflicts, breaches or violations as would not have a
material adverse effect on the transaction contemplated by this Agreement or the
Confirmation; and no consent, approval, authorization, order, registration or
qualification of or with any such court or governmental agency or body is
required for the consummation by SBC of the transactions contemplated by this
Agreement, except such as may be required under the Securities Act prior to the
resale of Shares and any such consents, approvals, authorizations, registrations
or qualifications as may be required under state securities or Blue Sky laws in
connection with the resale of Shares.
ARTICLE IV AGREEMENTS OF THE COMPANY
The Company agrees, with respect to the period beginning on the date hereof
through and including the earlier of the Termination Date or the date on which
the Company receives written notice from SBC that all of the Shares have been
resold (except that the provisions of Section 4.10 may continue by its terms
after such date), as follows:
4.1 Filing of Registration Statement. (a) The Company has filed or shall
--------------------------------
expeditiously file with the Commission a registration statement, covering the
resale of the Shares from time to time by SBC and such affiliated entities as
SBC may designate on securities exchanges or over-the-counter or in such other
lawful manner as SBC may specify, in a form previously reviewed by SBC.
(b) If such registration statement has not yet become effective, the
Company shall use its best efforts to cause such registration statement to
become effective no later than the Initial Date. The Company shall (i) use its
best efforts to cause such registration statement to remain in effect until the
earlier of the Termination Date or the date on which the Company receives
written notice from SBC that all of the Shares have been resold, (ii) inform SBC
promptly upon notice from the Commission that the Registration Statement has
been declared effective, (iii) advise SBC promptly of any proposed amendment or
supplement to the Prospectus after the effective date thereof and furnish SBC
with a draft prior to the filing thereof, (iv) for so long as delivery of a
prospectus is required in connection with the offering or sale of any of the
Shares, (A)
unless the Company is legally required to so amend or supplement the
Prospectus, (determined in the Company's sole and absolute discretion) make no
further amendment or any supplement to the Prospectus (other than any such
amendment or supplement resulting from the filing of reports or statements under
the Exchange Act which are incorporated by reference in the prospectus), after
the effective date thereof to which SBC reasonably objects within two business
days after receipt of a draft of the proposed amendment or supplement and (B)
file promptly all reports and any definitive proxy or information statements
required to be filed by the Company pursuant to Section 13(a), 13(c), 14 or
15(d) of the Exchange Act, (v) during such same period, advise SBC, promptly
after the Company receives notice thereof, (A) of the time when any amendment to
the Registration Statement has been filed or becomes effective or any supplement
to the Prospectus or any amended Prospectus has been filed with the Commission,
(B) of the issuance by the Commission of any stop order or of any order
preventing or suspending the use of any prospectus relating to the Shares, (C)
of the suspension of the qualification of the Shares for offering or sale in any
jurisdiction, (D) of the initiation or threatening of any proceeding for any
such purpose, or (E) of any request by the Commission for the amending or
supplementing of the Registration Statement or the Prospectus or for additional
information, and (vi) in the event of the issuance of any such stop order or of
any such order preventing or suspending the use of any prospectus relating to
the Shares or suspending any such qualification, use promptly its best efforts
to obtain the withdrawal of such order. The Company shall not include in the
Registration Statement any securities other than the Shares.
4.2 Qualification of the Shares under State Securities Laws . The Company
--------------------------------------------------------
shall promptly take, from time to time, such action as SBC may reasonably
request to qualify the Shares for offering and sale under the securities laws of
such of the United States as SBC may request and to comply with such laws so as
to permit the continuance of sales and dealings therein in such jurisdictions
for as long as may be necessary to complete the resale of the Shares (but not to
exceed the period specified in the first paragraph of this Article IV); provided
--------
that, in connection therewith, the Company shall not be required to qualify as a
- ----
foreign corporation or to file a general consent to service of process in any
jurisdiction.
4.3 Preparation of Registration Statement; Reasonable Investigation. The
---------------------------------------------------------------
Company shall (a) give SBC and its representatives the opportunity to
participate in the preparation of the Registration Statement and, to the extent
practicable, each amendment or supplement thereto and document incorporated by
reference therein which is filed with the Commission after the filing of the
Registration Statement (other than any such amendment or supplement resulting
from the filing of reports or statements under the Exchange Act which are
incorporated by reference in the prospectus), (b) give SBC and its
representatives such access to the books, records and properties of the Company
and its subsidiaries (to the extent customarily given to those who are
underwriters of the Company's securities) and such opportunities to discuss the
business of the Company with its officers and the independent public accountants
who have certified its financial statements and will have such officers and
accountants supply such information as shall be reasonably requested by SBC or
its representatives in connection with a "reasonable investigation" within the
meaning of Section 11(b) of the Securities Act and (c) furnish SBC with copies
of any press release or other public announcement which it intends to issue, or
any report or document which it intends to file under the Exchange Act with the
Commission or other regulatory agency, insofar as such press release, public
announcement, report or other document regards this Agreement and the Call
Warrant promptly and consider in good faith any comments received from SBC
concerning the timing and content of such press release, public announcement,
report or other document.
4.4 Compliance with Applicable Law and Commission Requirements. (a) The
----------------------------------------------------------
Registration Statement and Prospectus and all amendments or supplements thereto
shall conform in all material respects to the requirements of the Securities Act
and the rules and regulations of the Commission thereunder and shall not, as of
the applicable effective date as to the Registration Statement and any amendment
thereto and as of the applicable filing date of the Prospectus and any amendment
or supplement thereto, contain an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to
make the statements made therein, in the light of the circumstances under which
they were made, not misleading; provided, however, that this covenant shall not
apply to any statements or omissions made in reliance upon and in conformity
with information furnished in writing to the Company by SBC expressly for use in
the Prospectus or any amendment or supplement thereto.
(b) All of the documents incorporated by reference in the Registration
Statement and Prospectus, or any amendment or supplement thereto, whether
previously filed with the Commission or filed with the Commission following the
date hereof, at their respective times of filing, (i) shall have conformed or
shall conform, as applicable, in all material respects to the requirements of
the Securities Act or the Exchange Act, as applicable, and the rules and
regulations of the Commission thereunder and (ii) shall not have contained or
shall not contain, as applicable, an untrue statement of a material fact or omit
to state a material fact required to be stated therein or necessary in order to
make the statements made therein, in the light of the circumstances under which
they were made, not misleading; provided, however, that this representation and
warranty shall not apply to (A) any statements or omissions made in reliance
upon and in conformity with information furnished in writing to the Company by
or on behalf of SBC expressly for use in the Prospectus or any amendment or
supplement thereto or (B) statements or omissions that have been superseded or
otherwise corrected by an amendment, supplement or other filing under the
Exchange Act, but only with respect to the period after such correction.
4.5 Furnishing of Prospectuses; Notice to SBC of Need for Amendment. The
---------------------------------------------------------------
Company shall furnish SBC with copies of the Prospectus, including any
amendments or supplements thereto, in such quantities as SBC may from time to
time reasonably request. If, while the Registration Statement is effective, the
delivery of a prospectus is required at any time during the period specified in
the first paragraph of this Article IV
in connection with the offering and sale of the Shares by SBC and if, at such
time, any event shall have occurred as a result of which the Prospectus,
including the Prospectus as then amended or supplemented, would include an
untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements therein, in the light of the circumstances under
which they were made when such Prospectus is delivered, not misleading, or, if
for any other reason it shall be necessary during such same period to amend or
supplement the Prospectus or to file under the Exchange Act any document
incorporated by reference in the Prospectus in order to comply with the
Securities Act or the Exchange Act, the Company shall notify SBC in writing and,
as soon as reasonably practicable (in light of the nature of the event requiring
the amendment or supplement), provided that where such report is required under
this Section 4.5 solely to comply with the periodic reporting provisions under
the Exchange Act, such report need not be filed sooner than required by such
provisions and no such written notice to SBC shall be required, shall amend or
supplement the Prospectus or file such document so as to correct such statement
or omission or effect such compliance and shall prepare and furnish to SBC
without charge as many copies as SBC may from time to time reasonably request of
any amended Prospectus or supplement to the Prospectus.
4.6 Listing of the Shares. The Company shall use its best efforts to
---------------------
have the Shares approved for quotation on the Nasdaq National Market or listed
on such other exchange as the Common Stock is listed as of the Maturity Date.
4.7 Delivery of Opinion and Comfort Letter. On the effective date of the
--------------------------------------
Registration Statement, the Company shall cause to be furnished to SBC (i)an
opinion of counsel for the Company, dated the effective date of the Registration
Statement, in substantially the form of Exhibit A hereto and (ii)"comfort"
letters signed by the Company's independent public accountants who have examined
and reported on the Company's financial statements included in the Registration
Statement, to the extent permitted by the standards of the American Institute of
Certified Public Accounts, covering substantially the same matters with respect
to the Registration Statement (and the Prospectus) and with respect to events
subsequent to the date of the financial statements, as are customarily covered
in accountants' "comfort" letters delivered to the underwriters in underwritten
public offerings of securities.
If Applicable 4.8 Delivery of Prospectuses to the [Applicable Stock
-------------------------------------------------
Exchange]. The Company shall deliver to the [applicable stock exchange], for
- ---------
delivery to its members upon their request, such number of prospectuses as the
[applicable stock exchange] may require or request in order to permit SBC to
rely on Rule 153 under the Securities Act in meeting the prospectus delivery
requirements of Section 5(b)(2) of the Securities Act.
4.9 Furnishing of Additional Information. Until the earlier of the
------------------------------------
Termination Date or completion of resale of the Shares, the Company shall
furnish to SBC copies of all reports or other communications (financial or
other) generally furnished to stockholders and, as soon as they are available,
copies of any reports and financial
statements furnished to or filed with the Commission (other than requests for
confidential treatment filed with the Commission) or any national securities
exchange on which the Shares or any class of securities of the Company are
listed (such financial statements to be on a consolidated basis to the extent
the accounts of the Company and its subsidiaries are consolidated in reports
furnished to its stockholders generally or to the Commission).
4.10 Payment of Expenses. The Company shall pay or cause to be paid the
-------------------
following: (i) the fees, disbursements and expenses of the Company's counsel
and accountants in connection with the registration of the Shares and all other
expenses in connection with the preparation, printing and filing of the
Registration Statement, the Prospectus and any amendments and supplements
thereto and the mailing and delivering of copies thereof, (ii) any fees incurred
in connection with listing or approval for quotation of the Shares on the Nasdaq
National Market, (iii) all expenses in connection with the qualification of the
Shares for offering and sale under Section 4.2 hereof, (iv) the cost of
preparing certificates for the Shares, (v) the cost and charges of any transfer
agent or registrar or dividend disbursing agent, and (vi) all other costs
incident to the performance of the Company's obligations under Article IV hereof
which are not otherwise specifically provided for in this Section. It is
understood, however, that except as provided in this Section 4.10, SBC will pay
all of its own costs and expenses, including the fees of its counsel and
brokerage fees and commissions and transfer taxes on resale of any of the Shares
by SBC.
ARTICLE V AGREEMENTS OF SBC
SBC agrees, with respect to the period beginning on the date hereof through
and including the Termination Date, as follows:
5.1 Information for Use in the Prospectus. As soon as practicable but in
-------------------------------------
no event later than the third Local Business Day following the receipt of a
written request from the Company, SBC shall furnish the Company with such
information regarding SBC and its proposed dispositions of Shares as the Company
may from time to time reasonably request for use in preparing the Registration
Statement and Prospectus, including any amendments or supplements thereto, and
qualifying the Shares under state securities laws. The Company shall not be
obligated to register the Shares if SBC (or any affiliated entity of SBC) fails
to provide to the Company such information within the time period set forth
above.
5.2 Suspension of Disposition of Shares. Upon receipt of written notice
-----------------------------------
from the Company pursuant to Section 4.5 that an event has occurred as a result
of which, or that the Company has discovered that, the Prospectus, including the
Prospectus as then amended or supplemented, includes an untrue statement of a
material fact or omits to state any material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were
made, not misleading, or that for any other reason it shall be appropriate to
amend or supplement the Prospectus, SBC
shall immediately discontinue disposition of the Shares pursuant to the
Registration Statement until such time as SBC shall have received copies of an
amended or supplemented Prospectus or until it receives notice from the Company
that dispositions of Shares may be resumed without amendment or supplementation
of the Prospectus. The Termination Date shall be extended for an additional
number of Exchange Business Days during which SBC's right to sell the Shares was
suspended pursuant to the preceding sentence.
5.3 Notice of Completion. SBC shall notify the Company within three
--------------------
Local Business Days of completion of its disposition of the Shares.
5.4 Resales of Shares. SBC agrees that it will not offer, transfer, sell,
-----------------
pledge, hypothecate or otherwise dispose of any of the Shares (or solicit any
offers to buy, purchase or otherwise acquire or take a pledge of any Shares),
except in compliance with the Securities Act and the rules and regulations of
the Commission thereunder, and in compliance with applicable state securities or
Blue Sky laws.
ARTICLE VI INDEMNIFICATION
The Company and SBC further agree as follows:
6.1 Indemnification with Respect to the Registration Statement. (a) The
----------------------------------------------------------
Company will indemnify and hold harmless SBC against any losses, claims, damages
or liabilities, joint or several, to which SBC may become subject, under the
Securities Act, the Exchange Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon an untrue statement or alleged untrue statement of a material fact
contained in any Preliminary Prospectus, any preliminary prospectus supplement,
the Registration Statement, the Prospectus or any amendment or supplement
thereto, or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein in light of the circumstances in which they were made not
misleading, and will reimburse SBC for any legal or other expenses reasonably
incurred by SBC in connection with investigating or defending any such action or
claim as such expenses are incurred; provided, however, that the Company shall
not be liable in any such case to the extent that any such loss, claim, damage
or liability arises out of or is based upon an untrue statement or alleged
untrue statement or omission or alleged omission made in any Preliminary
Prospectus, any supplement thereto, the Registration Statement, the Prospectus
or any amendment or supplement thereto in reliance upon and in conformity with
written information furnished to the Company by SBC expressly for use therein.
The indemnity agreement contained in this Section 6.1(a) will not apply to
amounts paid in settlement of any such loss, claim, damage or liability if such
settlement is effected without the consent of the Company (which consent shall
not be unreasonably withheld).
(b) SBC will indemnify and hold harmless the Company against any losses,
claims, damages or liabilities to which the Company may become subject, under
the Securities Act, the Exchange Act or otherwise, insofar as such losses,
claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon an untrue statement or alleged untrue statement of a material
fact contained in any Preliminary Prospectus, any preliminary prospectus
supplement, the Registration Statement, the Prospectus and any amendment or
supplement thereto, or arise out of or are based upon the omission or alleged
omission to state therein a material fact required to be stated therein or
necessary to make the statements therein in light of the circumstances in which
they were made not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue statement or omission or
alleged omission was made in any Preliminary Prospectus, any preliminary
prospectus supplement, the Registration Statement, the Prospectus and any
amendment or supplement thereto in reliance upon and in conformity with written
information furnished to the Company by SBC expressly for use therein and will
reimburse the Company for any legal or other expenses reasonably incurred by the
Company in connection with investigating or defending any such action or claim
as such expenses are incurred., provided, however, that the obligations of SBC
under this Section 6.1(b) shall not apply to amounts paid in settlement of any
such loss, claim, damage or liability if such settlement is effected without the
consent of SBC (which consent shall not be unreasonably withheld).
(c) Each party entitled to indemnification under this Section 6.1 (the
"Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of such claim or any
litigation resulting therefrom, provided that counsel for the Indemnifying
Party, who shall conduct the defense of such claim or any litigation resulting
therefrom, shall be approved by the Indemnified Party (whose approval shall not
unreasonably be withheld), and the Indemnified Party may participate in such
defense at such party's expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 6.1 to the extent such
failure is not prejudicial. No Indemnifying Party in the defense of any such
claim or litigation shall, except with the consent of each Indemnified Party,
consent to entry of any judgement or enter into any settlement that does not
include as an unconditional term thereof, the giving by the claimant or
plaintiff to such Indemnified Party of a release from all liability in respect
to such claim or litigation and no Indemnified Party shall consent to entry of
any judgement or settle such claim or litigation without the prior written
consent of the Indemnifying Party, which consent shall not be unreasonably
withheld. Each Indemnified Party shall furnish such information regarding
itself or the claim in question as an Indemnifying Party may reasonably request
in writing and as shall be reasonably required in connection with defense of
such claim and litigation resulting therefrom.
(d) If the indemnification provided for in this Section 6.1 is unavailable
to or
insufficient to hold harmless an Indemnified Party under subsection (a) or (b)
above in respect of any losses, claims, damages or liabilities (or actions in
respect thereof) referred to therein, then each Indemnifying Party, in lieu to
indemnifying such Indemnified Party, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such losses, claims, damages or
liabilities (or actions in respect thereof) in such proportion as is appropriate
to reflect the relative fault of the Indemnifying Party on the one hand and the
Indemnified Party on the other in connection with the statements or omissions
which resulted in such losses, claims, damages or liabilities (or actions in
respect thereof), as well as any other relevant equitable considerations. The
relative fault shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the
Indemnifying Party on the one hand or the Indemnified Party on the other and the
parties' relative intent, knowledge, access to information and opportunity to
correct or prevent such statement or omission. The Company and SBC agree that it
would not be just and equitable if contribution pursuant to this subsection (d)
were determined by pro rata allocation or by any other method of allocation
which does not take account of the equitable considerations referred to above in
this subsection (d). The amount paid or payable by an Indemnified Party as a
result of the losses, claims, damages or liabilities (or actions in respect
thereof) referred to above in this subsection (d) shall be deemed to include any
legal or other expenses reasonably incurred by such Indemnified Party in
connection with investigating or defending any such action or claim. No person
guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any person who was
not guilty of such fraudulent misrepresentation.
(e) The obligations of the Company under this Section 6.1 shall be in
addition to any liability which the Company may otherwise have and shall extend,
upon the same terms and conditions, to each "affiliate" (as defined under the
Securities Act) of SBC, to each director and each officer of SBC and of its
affiliates, to each person, if any, who controls SBC or any of its affiliates
within the meaning of the Securities Act; and the obligations of SBC under this
Section 6.1 shall be in addition to any liability which SBC may otherwise have
and shall extend, upon the same terms and conditions, to each officer and
director of the Company and to each person, if any, who controls the Company
within the meaning of the Securities Act.
ARTICLE VII GENERAL
7.1 Notices. (a) Any notice or other communication in respect of this
-------
Agreement may be given in any manner set forth below to the address or number
specified in paragraph (b) of this Section 7.1 and will be deemed effective as
indicated: (i) if in writing and delivered in person or by courier, on the date
it is delivered; (ii) if sent by facsimile transmission, on the date that
transmission is received by a responsible employee of the recipient in legible
form (it being agreed that the burden of proving receipt will be on the sender
and will not be met by a
transmission report generated by the sender's facsimile machine); or (iii) if
sent by certified or registered mail or the equivalent (return receipt
requested), on the date that mail is delivered or its delivery is attempted;
unless that delivery (or attempted delivery) or that receipt, as applicable, is
not on a Local Business Day or occurs after the close of business on a Local
Business Day, in which case that notice or communication shall be deemed given
and effective on the first following day that is a Local Business Day.
(b) Notices shall be given to the addresses or facsimile numbers reflected
below:
If to SBC, to: Swiss Bank Corporation, London Branch
c/o SBC Warburg Inc.
141 West Jackson Boulevard
Chicago, Illinois 60604
Attention: Legal Department
Facsimile: (312) 554-5734
Telephone: (312) 554-5376
If to the Company, to: Myriad Genetics, Inc.
320 Wakara Way
Salt Lake City, Utah 84108
Attention: Jay M. Moyes, Vice President of Finance
Facsimile: (801) 854-3640
Telephone: (801) 854-3000
with a copy to:
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111
Attention: Jonathan L. Kravetz, Esq.
Facsimile: (617) 542-2241
Telephone: (617) 542-6000
(c) Either party may by notice to the other change the address or facsimile
number at which notices or other communications are to be given to it.
7.2 Entire Agreement. This Agreement, together with the Confirmation,
----------------
constitute the entire agreement and understanding of the parties with respect to
their subject matter and supersede all oral communications and prior writings
with respect thereto.
7.3 Governing Law and Jurisdiction. (a) This Agreement shall be governed
------------------------------
by and construed in accordance with New York law (without reference to choice of
law doctrine).
(b) With respect to any suit, action or proceedings relating to this
Agreement ("Proceedings"), each party irrevocably (i) submits to the non-
exclusive jurisdiction of the courts of the State of New York and the United
States District Court located in the Borough of Manhattan in New York City, and
(ii) waives any objection which it may have at any time to the laying of venue
of any Proceedings brought in any such court, waives any claim that such
Proceedings have been brought in an inconvenient forum and further waives the
right to object, with respect to such Proceedings, that such court does not have
any jurisdiction over such party. Nothing in this Agreement precludes either
party from bringing Proceedings in any other jurisdiction, nor will the bringing
of Proceedings in any one or more jurisdictions preclude the bringing of
Proceedings in any other jurisdiction.
(c) SBC hereby appoints Swiss Bank Corporation, New York Branch, 222
Broadway, New York, New York 10038, Attention: Legal Affairs, to receive, for
it and on its behalf, service of process of any Proceedings. The parties
irrevocably consent to service of process given in the manner provided for
notices in Section 7.1. Nothing in this Agreement will affect the right of
either party to serve process in any other manner permitted by law.
7.4 Amendments and Waivers. No amendment, modification or waiver in
----------------------
respect of this Agreement shall be effective unless in writing and executed by
each of the parties. A failure or delay in exercising any right, power or
privilege in respect of this Agreement shall not be presumed to preclude any
subsequent or further exercise of that right, power or privilege or the exercise
of any other right, power or privilege.
7.5 Remedies Cumulative. The rights, powers, remedies and privileges
-------------------
provided in this Agreement are cumulative and not exclusive of any rights,
powers, remedies and privileges provided by law.
7.6 Headings. The headings used in this Agreement are for convenience of
--------
reference only and shall not affect the construction of, or be taken into
consideration in interpreting, this Agreement.
7.7 No Third-Party Beneficiaries. Except as expressly provided in
----------------------------
Section 6.1(e), nothing in this Agreement is intended or shall be construed to
confer upon any person other than the parties hereto any right, remedy or claim
under or by reason of this Agreement.
7.8 Survival. The representations, warranties, indemnities and agreements
--------
contained in this Agreement shall remain in full force and effect, regardless of
any
investigation by or on behalf of any party, and shall survive delivery of
the Shares to SBC and resale of the Shares by SBC or any affiliated entity.
7.9 Counterparts. This Agreement may be executed in one or more
------------
counterparts with the same effect as if the signatures to each counterpart were
upon the same instrument.
7.10 Assignability. This Agreement is not assignable by either party
-------------
without the prior written consent of the other; provided that the Company may
assign this Agreement to a successor in interest pursuant to a transfer of all
or substantially all of its assets or pursuant to a consolidation or merger.
IN WITNESS WHEREOF, Myriad Genetics, Inc. and Swiss Bank Corporation,
London Branch, have executed this Agreement as of the day and year first written
above.
MYRIAD GENETICS, INC.
By: ____________________
Title:
SWISS BANK CORPORATION,
LONDON BRANCH
By: ____________________
Title:
By: ____________________
Title:
EXHIBIT 10.3
SCHEDULE
to the Master Agreement
dated as of October 8, 1997
between
SWISS BANK CORPORATION, and MYRIAD GENETICS, INC., a corporation
LONDON BRANCH organized under the laws of the State of
Delaware
("Party A") ("Party B")
PART 1
TERMINATION PROVISIONS
In this Agreement:
(a) "SPECIFIED ENTITY" means in relation to Party A for the purpose of:
Section 5(a)(v), NONE
Section 5(a)(vi), NONE
Section 5(a)(vii), NONE
Section 5(b)(iv), NONE
and in relation to Party B for the purpose of:
Section 5(a)(v), NONE
Section 5(a)(vi), NONE
Section 5(a)(vii), NONE
Section 5(b)(iv), NONE
(b) The definition of "SPECIFIED TRANSACTION" shall have the meaning specified
in Section 14 of the Agreement.
(c) The "CROSS DEFAULT" provisions of Section 5(a)(vi) will apply to both
parties but shall exclude any default that results solely from wire
transfer difficulties or an error or omission of an administrative or
operational nature (so long as sufficient funds are available to the
relevant party on the relevant date), but only if payment is made within
three Business Days after such transfer difficulties have been corrected or
the error or omission has been discovered.
If such provisions apply:
"SPECIFIED INDEBTEDNESS" means any obligation (whether present or future,
contingent or otherwise, as principal or surety or otherwise) in respect of
borrowed money or any Derivative Transaction other than any Specified
Transaction.
"THRESHOLD AMOUNT" means
(i) with respect to Party A, 2% of "Total Capital and Reserves" of Swiss Bank
Corporation as shown on the most recent annual audited financial statements
of Swiss Bank Corporation and
(ii) with respect to Party B, or any Specified Entity or Credit Support
Provider, the lesser of U.S. Dollars 10mm or 2% of the stockholders' equity
(however described) of Party B or the relevant Specified Entity or the
Credit Support Provider as shown on the most recent annual audited
financial statements of Party B or the relevant Specified Entity or the
Credit Support Provider.
(d) THE "CREDIT EVENT UPON MERGER" provisions of Section 5 (b)(iv) will not
apply to Party A or Party B.
(e) THE "AUTOMATIC EARLY TERMINATION" provision of Section 6 (a) will not apply
to Party A or Party B.
(f) "PAYMENTS ON EARLY TERMINATION". For the purpose of Section 6 (e) of this
Agreement:
(i) Loss will apply.
(ii) The Second Method will apply.
(g) "TERMINATION CURRENCY" means United States Dollars.
(h) "ADDITIONAL TERMINATION EVENT " will not apply.
PART 2
TAX REPRESENTATIONS
(a) Payer Representation. For the purpose of Section 3(e) of this Agreement,
Party A will make the following representation and Party B will make the
following representation:-
It is not required by any applicable law, as modified by the practice of
any relevant governmental revenue authority, of any Relevant Jurisdiction to
make any deduction or withholding for or on account of any Tax from any payment
(other than interest under Section 2(e), 6 (d) (ii) or 6 (e) of this Agreement)
to be made by it to the other party under this Agreement. In making this
representation, it may rely on (i) the accuracy of any representations made by
the other party pursuant to Section 3 (f) of this Agreement, (ii) the
satisfaction of the agreement contained in Section 4 (a)(iii) of this Agreement
and the accuracy and effectiveness of any document provided by the other party
pursuant to Section 4 (a)(i) or 4 (a)(iii) of this Agreement and (iii) the
satisfaction of the agreement of the other party contained in Section 4 (d) of
this Agreement, provided that it shall not be a breach of this representation
where reliance is placed on clause (ii) and the other party does not deliver a
form or document under Section 4 (a)(iii) by reason of material prejudice to its
legal or commercial position.
(b) Payee Representations. For the purpose of Section 3(f) of this Agreement,
Party A makes the following representation:
Each payment received or to be received by it in connection with this Agreement
will be effectively connected with its conduct of a trade or business in the
United States of America.
PART 3
AGREEMENT TO DELIVER DOCUMENTS
For the purpose of Sections 4(a) (i) and (ii) of this Agreement, each party
agrees to deliver the following documents, as applicable:
(a) Tax forms, documents or certificates to be delivered are:
PARTY REQUIRED TO FORM/DOCUMENT/CERTIFICATE DATE BY WHICH TO
DELIVER DOCUMENT BE DELIVERED
Party A Department of the Treasury On or before
Internal Revenue Service execution of
Form 4224 this Agreement
and on an annual
basis thereafter
Party B Department of the Treasury On or before execution
Internal Revenue Service Form of this Agreement
W-9
(b) Other documents to be delivered are:
PARTY REQUIRED TO DATE BY WHICH TO BE COVERED BY SECTION 3(D)
DELIVER DOCUMENT FORM/DOCUMENT/CERTIFICATE DELIVERED REPRESENTATION
Party A and Signature authentication On or before execution YES
Party B satisfactory the other of this Agreement
party hereto
Party B Copy (certified by an officer) On or before execution of YES
of the board resolution (or this Agreement
equivalent authorizing
documentation) permitting the
entering into of this Agreement
and Transactions hereunder
Party B Legal opinion satisfactory On or before execution of NO
to Party A regarding (inter this Agreement
alia) the ability of Party B
to enter into this Agreement
and Transactions hereunder
PART 4
MISCELLANEOUS
(a) ADDRESSES FOR NOTICES. For the purposes of Section 12(a) of this
Agreement:
(i) All notices or communications to Party A shall be sent to the address,
telex number, or facsimile number reflected below:
Address: Swiss Bank Corporation, London Branch, 1 High Timber Street,
London EC4V 3SB, Attention: Swaps Group, Telex: 887434, Answerback:
SBCO G
(ii) All notices or communications to Party B shall be sent to the address,
telex number, or facsimile number reflected below:
Address: Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108
Attention: Chief Financial Officer
Facsimile: 801-584-3640
(b) PROCESS AGENT. For the purpose of Section 13(c) of this Agreement:
Party A appoints as its Process Agent: Swiss Bank Corporation, New York
Branch, 222 Broadway, New York, NY 10038, Attention: Legal Affairs
Party B appoints as its Process Agent: N/A
(c) OFFICES. The provisions of Section 10(a) will apply to Party A and Party
B, it being the understanding of the parties that while obligations entered
into by an Office of a party pursuant to this Agreement constitute
obligations of the company (and not merely of such Office), each party
will, in respect of any Transaction and in the ordinary course of business,
send payments and notices to and receive payments and notices from the
Office of the other party specified in the Confirmation of such Transaction
rather than any other office of such party. A party (the "owed party") may
seek payment from the head office of the other party (the "owing party")
with
respect to this Agreement in the event that an amount payable to the
owed party by the owing party pursuant to this Agreement (including any
amount payable as a result of the occurrence or designation of an Early
Termination Date) has not been paid in full when due.
(d) MULTIBRANCH PARTY. For the purpose of Section 10(c) of this Agreement
neither Party A nor Party B is a Multibranch Party.
(e) CALCULATION AGENT. The Calculation Agent is Party A, unless otherwise
specified in a Confirmation in relation to the relevant Transaction.
(f) CREDIT SUPPORT DOCUMENT. Details of any Credit Support Document: NONE
(g) CREDIT SUPPORT PROVIDER. Credit Support Provider means: NOT APPLICABLE
(h) GOVERNING LAW. THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK (WITHOUT REFERENCE TO
CHOICE OF LAW DOCTRINE).
(i) NETTING OF PAYMENTS. Subparagraph (ii) of Section 2(c) of this Agreement
will apply.
(j) "AFFILIATE" will have the meaning specified in Section 14 of this
Agreement.
PART 5
OTHER PROVISIONS
(a) SET-OFF. Without affecting the provisions of the Agreement requiring the
--------
calculation of certain net payment amounts, all payments under this
Agreement will be made without set-off or counterclaim; provided, however,
that upon the designation of any Early Termination Date, in addition to and
not in limitation of any other right or remedy (including any right to set
off, counterclaim, or otherwise withhold payment or any recourse to any
Credit Support Document) under applicable law the Non-defaulting Party or
Non-affected Party (in either case, "X") may without prior notice to any
person set off any sum or obligation (whether or not arising under this
Agreement and whether matured or unmatured, whether or not contingent and
irrespective of the currency, place of payment or booking office of the sum
or obligation) owed by the Defaulting Party or Affected Party (in either
case, "Y") to X or any Affiliate of X against any sum or obligation
(whether or not arising under this Agreement, whether matured or unmatured,
whether or not contingent and irrespective of the currency, place of
payment or booking office of the sum or obligation) owed by X or any
Affiliate of X to Y. If any sum or obligation is unascertained, X may in
good faith estimate that sum or obligation and set-off in respect of that
estimate, subject to X or Y, as the case may be, accounting to the other
party when such sum or obligation is ascertained.
(b) REPRESENTATIONS AND WARRANTIES. Section 3(a) is amended by adding the
-------------------------------
following paragraphs (vi) and (vii):
"(vi) NO AGENCY. It is entering into this Agreement and each Transaction as
principal (and not as agent or in any other capacity, fiduciary or
otherwise).
(vii) ELIGIBLE SWAP PARTICIPANT. It is an "eligible swap participant" as
that term is defined by the United States Commodity Futures Trading
Commission in 17 C.F.R. (S)35.1(b)(2) and it has entered into this
Agreement and it is entering into each Transaction in connection with its
line of business (including financial intermediation services) or the
financing of its business; and the material terms of this Agreement and
such Transaction have been individually tailored and negotiated."
(c) RELATIONSHIP BETWEEN PARTIES. Each party will be deemed to represent to
-----------------------------
the other party on the date on which it enters into a Transaction that
(absent a written agreement between the parties that expressly imposes
affirmative obligations to the contrary for that Transaction):
(i) NON-RELIANCE. It is acting for its own account, and it has made its
own independent decisions to enter into that Transaction and as to whether that
Transaction is appropriate or proper for it based upon its own judgment and upon
advice from such advisers as it has deemed necessary. It is not relying on any
communication (written or oral) of the other party as investment advice or as a
recommendation to enter into that Transaction; it being understood that
information and explanations related to the terms and conditions of a
Transaction shall not be considered investment advice or a recommendation to
enter into that Transaction. No communication (written or oral) received from
the other party shall be deemed to be an assurance or guarantee as to the
expected results of that Transaction.
(ii) ASSESSMENT AND UNDERSTANDING. It is capable of assessing the merits
of and understanding (on its own behalf or through independent professional
advice), and understands and accepts the terms, conditions and risks of that
Transaction. It is also capable of assuming, and assumes, the risks of that
Transaction.
(iii) STATUS OF PARTIES. The other party is not acting as a fiduciary for
or an adviser to it in respect of that Transaction.
(d) TRANSFER. Section 7 is amended by the deletion of "and" at the end of
--------
paragraph (a), the deletion of the full stop at the end of paragraph (b) and the
insertion of a semi-colon followed by "and" in its place, and the insertion of a
new paragraph after paragraph (b) at the end thereof "(c) Party A may transfer
its rights and obligations under this Agreement in whole (but not in part) to
any branch of Swiss Bank Corporation provided that as a result of such transfer:
(i) it does not become unlawful for either party to perform any obligation
under this Agreement;
(ii) neither party is required to pay to the other party an additional
amount under Section 2(d)(i)(4) or to receive a payment from which an amount is
required to be deducted or withheld for or on account of a Tax and no additional
amount is required to be paid in respect of such Tax under Section 2(d)(i)(4);
and
(iii) no Event of Default occurs in respect of either party."
(e) WAIVER OF JURY TRIAL. Each party hereby irrevocably waives any and all
---------------------
right to trial by jury in any suit, action or proceeding arising out of or
relating to this Agreement or any Transaction and acknowledges that this waiver
is a material inducement to the other party's entering into this Agreement.
(f) CONSENT TO RECORDING. The parties agree that each may electronically
---------------------
record all telephonic conversations between them and that any such
recordings may be submitted in evidence to any court or in any Proceedings
for the purpose of establishing any matters pertinent to any Transaction,
provided any such conversation is on a telephone line emitting an audible
tone indicating that such line is being recorded.
(g) SEVERANCE. In the event any one or more of the provisions contained in
----------
this Agreement should be held invalid, illegal or unenforceable in any
respect, such provisions shall be severed from this Agreement to the extent
of such invalidity, illegality or unenforceability, unless such severance
shall substantially impair the benefits of the remaining portions of this
Agreement. The Agreement after such severance shall remain the valid,
binding and enforceable obligation of the parties hereto.
(h) NETTING PROVISIONS. If an Early Termination Date occurs, amounts
-------------------
determined in respect of all Terminated Transactions shall be aggregated
with and netted against one another in performing the calculations
contemplated by Section 6(e). If the calculation of the amount payable
pursuant to Section 6(e) in respect of an Early Termination Date would
involve the aggregation or netting of amounts determined in respect of
Transactions of different types, and
under applicable law amounts determined in respect of one or more types of
Transactions hereunder may not be aggregated with or netted against amounts
determined in respect of one or more other types of Transactions in performing
such calculation, then, notwithstanding the foregoing or any other provision of
this Agreement, aggregation and netting will be performed within and between
types of Transactions to the fullest extent permitted by law in performing such
calculation, and the set-off provisions of this Agreement and applicable law
shall be applied to the resulting amount or amounts.
(i) DEFINITIONS. The following definition shall appear in Section 14 after the
------------
definition of "Defaulting Party":
"'Derivative Transaction' means:
(a) any transaction (including an agreement with respect thereto) which is a
rate swap transaction, basis swap, forward rate transaction, commodity
swap, commodity option, equity or equity index swap, equity or equity index
option, bond option, interest rate option, foreign exchange transaction,
repurchase transaction, reverse repurchase transaction, precious metals
transaction, cap transaction, floor transaction, collar transaction,
currency swap transaction, cross-currency rate swap transaction, currency
option or any other similar transaction (including any option with respect
to any of these transactions); and
(b) any combination of these transactions."
(j) ONE-WAY TRANSACTION. Party B agrees that in the event the parties enter
-------------------
into a Transaction, other than a call option transaction written by either
Party A or Party B where the property underlying the transaction is the
common stock of Party B, then Party B will enter into a new Master
Agreement with Party A or will amend this Agreement, in either case in a
form satisfactory to Party A and Party B.
PART 6
ADDITIONAL TERMS FOR EQUITY AND EQUITY INDEX TRANSACTIONS
Notwithstanding anything to the contrary in this Agreement, the following
provisions will apply for the purposes of any Transaction which is an option on
a single security, a basket of securities or an index, including any Transaction
which contemplates by its terms the physical delivery of shares, participation
certificates or other equity securities ("Shares"):
(a) DIVIDENDS AND EXPENSES. The following provision shall be included as
----------------------
Section 2(f):
"(f) DIVIDENDS AND EXPENSES ON DELIVERY: All dividends on the Shares to be
delivered shall be payable to and all costs and expenses incurred in connection
with the delivery of Shares (including, without prejudice to Section 2(d), any
Tax or Stamp Tax and any interest or penalties payable in connection therewith)
shall be payable by the party who would customarily receive such dividend or
bear such costs or expenses under a contract for the purchase of the Shares by
the deliveree through the clearance system specified in the relevant
Confirmation."
(b) DEFAULT INDEMNITY. If prior to the occurrence or effective designation of
-----------------
an Early Termination Date in respect of any Transaction a party defaults in
the performance of any obligation under such Transaction required to be
settled by delivery, it will indemnify the other party on demand for any
reasonable costs, losses or expenses (including the costs of borrowing
Shares, if applicable) resulting from such default.
(c) REPRESENTATIONS. Each party acknowledges that (i) certain Transactions may
---------------
be securities that have not been registered under the Securities Act of
1933 of the United States of America, as amended (the "1933 Act"), or under
the laws of any state, (ii) no federal or state agency has passed upon such
Transactions or made any finding or determination as to the
fairness of such Transactions and (iii) such Transactions are intended to
be exempt from registration under the 1933 Act. In addition to the
representations made pursuant to Section 3 of this Agreement,each party
represents to the other party with respect to any such Transaction that (i)
it is an "accredited investor," as such term is defined in Regulation D
promulgated under the 1933 Act, (ii) it has had access to such information
regarding such Transaction and the other party as it requested, (iii) it
has knowledge and experience in financial and business matters and is
capable of evaluating the merits and risks of such Transaction and is able
to bear the economic risk of its investment, including without limitation
the risk of complete loss on the investment, (iv) it acquired its interest
in such Transaction for its own account for investment and not with a view
to, or in connection with, any distribution of such interests, (v) it will
not sell, transfer, assign or otherwise dispose such Transaction or
interests herein and therein in violation of the 1933 Act and the rules and
regulations promulgated thereunder, and (vi) with respect to any
Transaction which contemplates by its terms the physical delivery of
Shares, at the time of the delivery of any such Shares to the other party,
it possesses full legal and beneficial title thereto and it is delivering
the same free and clear of any lien, claim, encumbrance or security
interest of any kind whatsoever created by the deliveror.
EXHIBIT 10.4
CONFIRMATION
Date: October 22, 1997
To: Myriad Genetics, Inc. ("Party B")
Attention: Jay Moyes
From: Swiss Bank Corporation, London Branch ("Party A")
Re: Equity Option Confirmation
Reference Number 1265547/1265545
_______________________________________________________________________
The purpose of this communication is to confirm the terms and conditions of the
transaction (the "Transaction") entered into between us on the Trade Date
specified below.
The definitions and provisions contained in the 1991 ISDA Definitions (as
published by the International Swaps and Derivatives Association, Inc. (formerly
known as the International Swap Dealers Association, Inc.) ("ISDA")) are
incorporated into this Confirmation. In the event of any inconsistency between
those definitions and provisions and this Confirmation, this Confirmation will
govern.
This Confirmation supplements, forms part of, and is subject to, the ISDA Master
Agreement dated as of October 8, 1997, as amended and supplemented from time to
time (the "Agreement"), between you and Swiss Bank Corporation. All provisions
contained in the Agreement govern this Confirmation except as expressly modified
below.
The terms of the Transaction to which this Confirmation relates are as follows:
Trade Date : October 21, 1997
Buyer : Party B
Seller : Party A
Option Style : European Option
Option Type : Capped Call
Shares : Common Stock of Myriad Genetics, Inc. (Symbol: MYGN)
Number of Options : 400,000
Contract Multiplier : 1.00
Strike Price : USD 32.25
Cap Price : USD 40.50
Total Premium : Call options written by Party B on 400,000 shares
of Party B's Common Stock.
Premium
Payment Date : n/a
Expiration Date : December 11, 1998, or, if that date is not an
Exchange Business Day, the following day that is an
Exchange Business Day.
Currency
Business Day : Any day on which commercial banks are open for
business (including dealings in foreign exchange and
foreign currency deposits) in the cities from which
and in which a payment is to be made.
Exchange
Business Day : A day that is (or but for the occurrence of a Market
Disruption Event, would have been) a trading day on
the Exchange and the Philadelphia Stock Exchange
(other than a day on which trading on any such
exchange is scheduled to close prior to its regular
weekday closing time, first announced on the day of
such closing).
Normal
Trading Day : An Exchange Business Day on which no Market
Disruption Event has occurred or is continuing.
Market
Disruption Event : The occurrence or existence on any Exchange Business
Day during the one-half hour period that ends at the
close of business of any suspension of or limitation
imposed on trading (by reason of movements in price
exceeding levels permitted by the relevant exchange
or otherwise), provided that any such event is
material in the reasonable determination of the
Calculation Agent, on: (i) the Exchange in the
Shares; or (ii) the Philadelphia Stock Exchange in
options contracts on the Shares.
Exchange : Nasdaq National Market
Clearance System
Business Day : Any day on which the Clearance System is open for
the acceptance and execution of settlement
instructions.
Clearance System : Depository Trust Company, or any successor to or
transferee of such clearance system.
Calculation Agent : Party A, whose calculations shall be binding absent
manifest error.
Procedure for Exercise
- ----------------------
Exercise Date : The Expiration Date.
Expiration Time : 5:00 p.m. local time in New York City.
Automatic Exercise : The Transaction will be deemed to be automatically
exercised if it is In-the-Money on the Expiration
Date, unless (i) the Buyer has notified the Seller
or its agent (by telephone or in writing) prior to
5:00 p.m. local time in New York City on the
Expiration Date that it does not wish to exercise
the Transaction; or (ii) the Closing Value cannot be
determined on the Expiration Date. If the
Transaction is to be cash settled, "In-the-Money"
means that the Cash Settlement Amount is greater
than zero. If the Transaction is to be physically
settled, "In-the-Money" means that the Closing Value
is greater than the Strike Price. "Closing Value"
means the closing price of the Shares, as reported
on the Exchange, on the Expiration Date.
Telephone
or facsimile number
of Seller's agent
for purposes of
giving notice : Telephone: 312-554-5249
Fax: 312-554-6271
Attention: David P. Stowell
Settlement Terms
- ----------------
Settlement : The Transaction will be cash settled; provided,
however, that Party B may elect to physically settle
the Transaction by giving notice to Party A no later
than 20 Exchange Business Days before the Expiration
Date (determined without regard to the parenthetical
in the definition of Exchange Business Day).
Physical Settlement : If the Transaction is to be physically settled, on
the Settlement Date, the Seller shall deliver to the
Buyer the number of Shares equal to the number of
Options exercised against payment by the Buyer to
the Seller of an amount equal to the product of (a)
the Strike Price, adjusted as hereinafter provided,
multiplied by (b) the number of Options exercised.
If the Closing Value exceeds the Cap Price, the
Strike Price shall be increased by the amount by
which the Closing Value exceeds the Cap Price; if
the Closing Value is equal to or less than the Cap
Price, no adjustment will be made to the Strike
Price. Such payment and such delivery will be made
through the Clearance System at the accounts
specified below, on a delivery versus payment basis.
Cash Settlement : If the Transaction is to be cash settled, on the
Settlement Date, Party A shall pay to Party B the
Cash Settlement Amount, if any. The "Cash Settlement
Amount" shall be the greater of (a) zero and (b) an
amount calculated by the Calculation Agent equal to
(i) the number of Options exercised multiplied by
(ii) the Price Differential. "Price Differential"
means (x) if the Reference Price exceeds the Cap
Price, the result of subtracting the Strike Price
from the Cap Price, and (y) if the Reference Price
is equal to or less than the Cap Price, the result
of subtracting the Strike Price from the Reference
Price.
Reference Price : (a) If the Valuation Period contains fifteen
Normal Trading Days, the Reference Price shall be
the arithmetic average of the Share Prices on those
fifteen Normal Trading Days.
(b) If the Valuation Period does not contain
fifteen Normal Trading Days, the Calculation Agent
shall determine the Share Price for the Valuation
Date and as many Exchange Business Days immediately
preceding the Valuation Date as shall be necessary,
when such Share Prices are taken together with the
Share Prices on all Normal Trading Days occurring
within the Valuation Period, to provide fifteen
Share Prices, and in such case the Reference Price
shall be the arithmetic average of those fifteen
Share Prices.
Share Price : The closing price of the Shares as reported on the
Exchange.
Valuation Period : The period from and including the fourteenth
Exchange Business Day immediately preceding the
Expiration Date (the "Initial Date") to and
including the Expiration Date, provided that if any
Exchange Business Day in the Valuation Period as so
determined, shall not be a Normal Trading Day, the
Valuation Period shall be extended so that the
Valuation Period includes fifteen Normal Trading
Days , but in no event shall the last day of the
Valuation Period be later than the fifteenth
Exchange Business Day after the Expiration Date, and
in no event shall the Valuation Period include any
day before the Initial Date.
Valuation Date : The last day of the Valuation Period.
Settlement Date : If the Transaction is to be cash settled, the
Settlement Date shall be three Currency Business
Days after the Valuation Date. If the Transaction is
to be physically settled, the Settlement Date shall
be three Clearance System Business Days after the
Exercise Date.
Adjustment Events
- -----------------
Adjustments : During the life of the Transaction, if any
adjustment is made by The Options Clearing
Corporation or its successors ("OCC") in the terms
of outstanding OCC-issued options ("OCC Options") on
the Shares which are the subject of the
Transactions, an equivalent adjustment shall be made
in the terms of the Transaction. Except as provided
in the following paragraph and in the "Additional
Adjustment Provisions" below, no adjustment shall be
made in the terms of the Transaction for any event
that does not result in an adjustment to the terms
of outstanding OCC Options on the Shares. Without
limiting the generality of the foregoing, NO
ADJUSTMENT SHALL BE MADE IN THE TERMS OF THE
TRANSACTIONS FOR ORDINARY CASH DIVIDENDS ON THE
SHARES EXCEPT AS PROVIDED IN THE "ADDITIONAL
ADJUSTMENTS" PROVISIONS BELOW.
If at any time during the life of the Transaction
there shall be no outstanding OCC Options on the
Shares, and an event shall occur for which an
adjustment might otherwise be made under the By-
Laws, Rules, and stated policies of the OCC
applicable to the adjustment of OCC Options (the
"OCC Adjustment Rules"), the parties shall use their
best
efforts, applying the principles set forth in the
OCC Adjustment Rules, to jointly determine whether
to adjust the terms of the Transaction and the
nature of any such adjustment.
Additional
Adjustments : Notwithstanding the foregoing, if upon the
occurrence of the following events during the life
of the Transaction no adjustment is required to be
made to the terms of the Transaction in accordance
with the foregoing provisions or if an adjustment
has been made but such adjustment is, in the
reasonable determination of the Calculation Agent,
insufficient to preserve the economic benefit of the
Transaction for the parties, the following
additional adjustments shall be made to the terms of
the Transaction:
If (a) an ordinary cash dividend is declared or paid
on the Shares or (b) a special cash dividend is
declared or paid on the Shares and in either case
the Ex-Dividend Date with respect to such dividend
occurs during the period from, and including, the
Effective Date to, but excluding, the Expiration
Date (each, a "Dividend Event"), the Strike Price
and the Cap Price shall each be adjusted for each
Dividend Event in accordance with the following
formulas:
SP\\0\\ (CP\\0\\ - DA)
----------------------
SP\\1 \\ = CP\\0\\
C\\0\\ (CP\\0\\ - DA)
---------------------
C\\1 \\ = CP\\0\\
Where:
(i) SP\\1\\ = Strike Price after the Dividend
Event
(ii) C\\1\\ = Cap Price after the Dividend Event
(iii) SP\\0\\ = Strike Price on the Exchange
Business Day immediately preceding the
Ex-Dividend Date with respect to the
Dividend Event
(iv) C\\0\\ = Cap Price on the Exchange Business
Day immediately preceding the Ex-Dividend
Date with respect to the Dividend Event
(v) CP\\0\\ = The closing price of the Shares, as
reported on the Exchange, on the Exchange
Business Day immediately preceding the
Ex-Dividend Date with respect to the
Dividend Event
(vi) DA = The amount of the ordinary cash dividend
or the special cash dividend, as the case
may be
Miscellaneous
- -------------
Transfer : Neither party may transfer the Transaction, in
whole or in part, without the prior written
consent of the non-transferring party.
Account Details
- ---------------
Payments and deliveries to Party A:
Account for payments: Previously Provided
Delivery instructions: Previously Provided
Payments and deliveries to Party B:
Account for payments: Previously Provided
Delivery instructions: Previously Provided
Please confirm that the foregoing correctly sets forth the terms of our
agreement by executing the copy of this Confirmation enclosed for that purpose
and returning it to us or by sending to us a letter or telex substantially
similar to this letter, which letter or telex sets forth the material terms of
the Transaction to which this Confirmation relates and indicates your agreement
to those terms.
Yours sincerely,
SWISS BANK CORPORATION, LONDON BRANCH
By: /s/ Victoria Harkness Sotgiu By: /s/ John Marshall
---------------------------- ----------------------------
Name: Victoria Harkness Sotgiu Name: John Marshall
Title: Authorised Signatory Title: Authorised Signatory
Confirmed as of the 22nd day
of October, 1997
MYRIAD GENETICS, INC.
By: /s/ Jay M. Moyes
----------------------------
Name: Jay M. Moyes
Title: C.F.O.
EXHIBIT 10.5
CONFIRMATION
Date: October 22, 1997
To: Myriad Genetics, Inc. ("Party B")
Attention: Jay Moyes
From: Swiss Bank Corporation, London Branch ("Party A")
Re: Equity Option Confirmation
Reference Number 1265546
_______________________________________________________________________________
The purpose of this communication is to confirm the terms and conditions of the
transaction (the "Transaction") entered into between us on the Trade Date
specified below.
The definitions and provisions contained in the 1991 ISDA Definitions (as
published by the International Swaps and Derivatives Association, Inc. (formerly
known as the International Swap Dealers Association, Inc.) ("ISDA")) are
incorporated into this Confirmation. In the event of any inconsistency between
those definitions and provisions and this Confirmation, this Confirmation will
govern.
This Confirmation supplements, forms part of, and is subject to, the ISDA Master
Agreement dated as of October 8, 1997, as amended and supplemented from time to
time (the "Agreement"), between you and Swiss Bank Corporation. All provisions
contained in the Agreement govern this Confirmation except as expressly modified
below.
The terms of the Transaction to which this Confirmation relates are as follows:
Trade Date : October 21, 1997
Buyer : Party A
Seller : Party B
Option Style : European Option
Option Type : Call
Shares : Common Stock of Myriad Genetics, Inc.
(Symbol: MYGN)
Number of Options : 400,000
Contract Multiplier : 1.00
Strike Price : USD 40.50
Total Premium : USD 100,000 and call options written by Party A on
400,000 shares of Party B's Common Stock. Premium
Payment Date : October 24, 1997
Expiration Date : December 11 1998, or, if that date is not an
Exchange Business Day, the following day that is an
Exchange Business Day.
Currency
Business Day : Any day on which commercial banks are open for
business (including dealings in foreign exchange and
foreign currency deposits) in the cities from which
and in which a payment is to be made.
Exchange
Business Day : A day that is (or but for the occurrence of a Market
Disruption Event, would have been) a trading day on
the Exchange and the Philadelphia Stock Exchange
(other than a day on which trading on any such
exchange is scheduled to close prior to its regular
weekday closing time, first announced on the day of
such closing).
Normal
Trading Day : An Exchange Business Day on which no Market
Disruption Event has occurred or is continuing.
Market
Disruption Event : The occurrence or existence on any Exchange Business
Day during the one-half hour period that ends at the
close of business of any suspension of or limitation
imposed on trading (by reason of movements in price
exceeding levels permitted by the relevant exchange
or otherwise), provided that any such event is
material in the reasonable determination of the
Calculation Agent, on: (i) the Exchange in the
Shares; or (ii) the Philadelphia Stock Exchange in
options contracts on the Shares.
Exchange : Nasdaq National Market
Clearance System
Business Day : Any day on which the Clearance System is open for
the acceptance and execution of settlement
instructions.
Clearance System : Depository Trust Company, or any successor to or
transferee of such clearance system.
Calculation Agent : Party A, whose calculations shall be binding absent
manifest error.
Procedure for Exercise
- ----------------------
Exercise Date : The Expiration Date.
Expiration Time : 5:00 p.m. local time in New York City.
Automatic Exercise : The Transaction will be deemed to be automatically
exercised if it is In-the-Money on the Expiration
Date, unless (i) the Buyer has notified the Seller
(by telephone or in writing) prior to 5:00 p.m.
local time in New York City on the Expiration Date
that it does not wish to exercise the Transaction;
or (ii) the Closing Value cannot be determined on
the Expiration Date. If the Transaction is to be
cash settled or net share settled, "In-the-Money"
means that the Cash Settlement Amount is greater
than zero. If the Transaction is to be physically
settled, "In-the-Money" means that the Closing Value
is greater than the Strike Price. "Closing Value"
means the closing price of the Shares, as reported
on the Exchange, on the Expiration Date.
Seller's telephone
or facsimile number
for purposes of
giving notice : Telephone: 801-584-3633
Fax: 801-584-3640
Attention: Jay Moyes
Settlement Terms
- ----------------
Settlement : The Transaction will be physically settled;
provided, however, that Party B may elect to cash
settle or net share
settle the Transaction by giving notice to Party A
no later than 20 Exchange Business Days before the
Expiration Date (determined without regard to the
parenthetical in the definition of Exchange Business
Day) (the date of such notice, the "Election Date").
Notwithstanding the foregoing, if on the Initial
Date (as defined below) the registration statement
referred to in Section 4.1 of the Agreement
Regarding Registration Rights and Related
Obligations (the "Registration Agreement") attached
hereto as Exhibit I has not become effective, the
Transaction will be cash settled and the parties
shall have no further obligations under the
Registration Agreement.
Physical Settlement : If the Transaction is to be physically settled:
(a) within three Exchange Business Days after the
Election Date, Party A and Party B will enter into
the Registration Agreement attached hereto as
Exhibit I; and
(b) on the Settlement Date, the Seller shall
deliver to the Buyer the number of Shares equal to
the number of Options exercised against payment by
the Buyer to the Seller of an amount equal to the
product of (A) the Strike Price multiplied by (B)
the number of Options exercised. Such payment and
such delivery will be made through the Clearance
System at the accounts specified below, on a
delivery versus payment basis.
Cash Settlement : If the Transaction is to be cash settled:
(a) within one Currency Business Day after written
notice by Party A, Party B will pay to Party A the
Prepayment Amount. The "Prepayment Amount" shall be
an amount calculated by the Calculation Agent equal
to (i) the number of Options to be exercised
multiplied by (ii) the result of subtracting the
Strike Price from the closing price of the Shares,
as reported on the Exchange, on the Election Date.
(b) on the Settlement Date, the following payment
shall be made:
(i) if a Prepayment Amount has been paid by
Party B, then (A) if the Final Payment Amount
is a positive number, Party B shall pay to
Party A an amount equal to the Final Payment
Amount and (B) if the Final Payment Amount is a
negative number,
Party A shall pay to Party B an amount equal to
the absolute value of the Final Payment Amount.
The "Final Payment Amount" shall be an amount,
which may be less than zero, calculated by the
Calculation Agent equal to (A) the Cash
Settlement Amount minus (B) the Prepayment
Amount minus (C) the Interest Amount. The "Cash
Settlement Amount" shall be the greater of (A)
zero and (B) an amount calculated by the
Calculation Agent equal to (1) the number of
Options exercised multiplied by (2) the result
of subtracting the Strike Price from the
Reference Price. The "Interest Amount" shall be
an amount calculated by the Calculation Agent
equal to the aggregate sum of the amounts of
interest calculated for each day in the period
from (and including) the date the Prepayment
Amount is received by Party A to (but
excluding) the Settlement Date, determined as
follows: (A) the Prepayment Amount multiplied
by (B) the overnight Federal Funds Rate for
such day as reported in Federal Reserve
Publication H.15-519 divided by (C) 360.
(ii) if a Prepayment Amount has not been paid
by Party B, Party B shall pay to Party A the
Cash Settlement Amount, if any.
Reference Price : (a) If the Valuation Period contains fifteen Normal
Trading Days, the Reference Price shall be the
arithmetic average of the Share Prices on those
fifteen Normal Trading Days.
(b) If the Valuation Period does not contain fifteen
Normal Trading Days, the Calculation Agent shall
determine the Share Price for the Valuation Date and
as many Exchange Business Days immediately preceding
the Valuation Date as shall be necessary, when such
Share Prices are taken together with the Share
Prices on all Normal Trading Days occurring within
the Valuation Period, to provide fifteen Share
Prices, and in such case the Reference Price shall
be the arithmetic average of those fifteen Share
Prices.
Share Price : The closing price of the Shares as reported on the
Exchange.
Valuation Period : The period from and including the fourteenth
Exchange
Business Day immediately preceding the Expiration
Date (the "Initial Date") to and including the
Expiration Date, provided that if any Exchange
Business Day in the Valuation Period as so
determined, shall not be a Normal Trading Day, the
Valuation Period shall be extended so that the
Valuation Period includes fifteen Normal Trading
Days , but in no event shall the last day of the
Valuation Period be later than the fifteenth
Exchange Business Day after the Expiration Date, and
in no event shall the Valuation Period include any
day before the Initial Date.
Valuation Date : The last day of the Valuation Period.
Net Share
Settlement : If a Transaction is to be net share settled,
(a) within three Exchange Business Days after the
Election Date, Party A and Party B will enter into
the Registration Agreement attached hereto as
Exhibit I; and
(b) on the Settlement Date, Party B shall deliver to
Party A the number of whole Shares (the "Settlement
Shares") equal to (i) the Cash Settlement Amount
divided by (ii) the Closing Value, plus cash in lieu
of any fractional Shares. If within ten Exchange
Business Days after the Settlement Date, Party A
resells all or any portion of the Settlement Shares
and the net proceeds received by the Party A upon
resale of such Shares exceed the Cash Settlement
Amount (or if less than all of the Settlement Shares
are resold, the applicable pro rata portion of the
Cash Settlement Amount), Party A shall promptly
refund in cash such difference to Party B. In the
event that such net proceeds are less than the Cash
Settlement Amount (or if less than all of the
Settlement Shares are resold, the applicable pro
rata portion of the Cash Settlement Amount), Party B
shall pay in cash or additional Shares such
difference (the "Make-whole Amount") to Party A
promptly after receipt of notice thereof. In the
event that Party B elects to pay the Make-whole
Amount in additional Shares, Party B shall deliver
to Party A the number of whole Shares (the "Make-
whole Shares") equal to (i) the Make-whole Amount
divided by (ii) the closing price of the Shares as
reported on the Exchange on the Exchange Business
Day prior to delivery of such Shares. If within ten
Exchange Business Days after the delivery of the
Make-whole Shares to Party A, Party A resells all or
any portion of such Shares and the net
proceeds received by Party A exceed or are less than
the Make-whole Amount (or if less than all of the
Make-whole Shares are resold, the applicable pro
rata portion of the Make-whole Amount), the
provisions set forth above with respect to payment
of the Settlement Payment in Shares, including Make-
whole requirements, shall apply.
Settlement Date : If the Transaction is to be cash settled, the
Settlement Date shall be three Currency Business
Days after the Valuation Date. If the Transaction is
to be physically settled or net share settled, the
Settlement Date shall be three Clearance System
Business Days after the Exercise Date.
Change in Expiration Date
- -------------------------
Delay of Expiration
Date : At any time prior to fifteen days prior to the date
that otherwise would have been the Expiration Date,
Party B may notify Party A that it would like to
delay the Expiration Date to a date (the
"Termination Date") not less than ten Exchange
Business Days after the date of such notice and not
more than 180 days after the original Expiration
Date. Promptly after receipt of such notice, Party A
shall notify Party B of the additional amount, if
any, required to be paid (the "Settlement Amount")
by the Buyer of the Transaction to compensate the
Seller of the Transaction for such delay. The
Settlement Amount shall be reasonably determined by
Party A based upon Party A's then current
methodology for pricing options. Within five
Exchange Business Days after receipt of notice of
the Settlement Amount from Party A, Party B shall
notify Party A whether it agrees to the Settlement
Amount (the date of such notice, the "Agreement
Date"). If Party B agrees to the Settlement Amount
(i) the Termination Date shall be deemed to be the
Expiration Date for all purposes of this
Confirmation; and (ii) the Settlement Amount, which
shall be in addition to any payment or delivery, if
any, otherwise required to be made under the terms
of the Transaction, shall be paid by the Buyer on
the third Currency Business Day after the Agreement
Date. If Party B does not agree to the Settlement
Amount, the Expiration Date shall not be delayed.
Adjustment Events
- -----------------
Adjustments : During the life of the Transaction, if any
adjustment is made
by The Options Clearing Corporation or its
successors ("OCC") in the terms of outstanding OCC-
issued options ("OCC Options") on the Shares which
are the subject of the Transactions, an equivalent
adjustment shall be made in the terms of the
Transaction. Except as provided in the following
paragraph and in the "Additional Adjustment
Provisions" below, no adjustment shall be made in
the terms of the Transaction for any event that does
not result in an adjustment to the terms of
outstanding OCC Options on the Shares. Without
limiting the generality of the foregoing, NO
ADJUSTMENT SHALL BE MADE IN THE TERMS OF THE
TRANSACTIONS FOR ORDINARY CASH DIVIDENDS ON THE
SHARES EXCEPT AS PROVIDED IN THE "ADDITIONAL
ADJUSTMENTS" PROVISIONS BELOW.
If at any time during the life of the Transaction
there shall be no outstanding OCC Options on the
Shares, and an event shall occur for which an
adjustment might otherwise be made under the By-
Laws, Rules, and stated policies of the OCC
applicable to the adjustment of OCC Options (the
"OCC Adjustment Rules"), the parties shall use their
best efforts, applying the principles set forth in
the OCC Adjustment Rules, to jointly determine
whether to adjust the terms of the Transaction and
the nature of any such adjustment.
Additional
Adjustments : Notwithstanding the foregoing, if upon the
occurrence of the following events during the life
of the Transaction no adjustment is required to be
made to the terms of the Transaction in accordance
with the foregoing provisions or if an adjustment
has been made but such adjustment is, in the
reasonable determination of the Calculation Agent,
insufficient to preserve the economic benefit of the
Transaction for the parties, the following
additional adjustments shall be made to the terms of
the Transaction:
If (a) an ordinary cash dividend is declared or paid
on the Shares or (b) a special cash dividend is
declared or paid on the Shares and in either case
the Ex-Dividend Date with respect to such dividend
occurs during the period from, and including, the
Effective Date to, but excluding, the Expiration
Date (each, a "Dividend Event"), the Strike Price
shall be adjusted for each Dividend Event in
accordance with the following formula:
SP\\0\\ (CP\\0\\ - DA)
----------------------
SP\\1 \\ = CP\\0\\
Where:
(i) SP\\1\\ = Strike Price after the Dividend
Event
(ii) SP\\0\\ = Strike Price on the Exchange
Business Day immediately preceding the Ex-
Dividend Date with respect to the Dividend
Event
(iii) CP\\0\\ = The closing price of the Shares, as
reported on the Exchange, on the Exchange
Business Day immediately preceding the Ex-
Dividend Date with respect to the Dividend
Event
(iv) DA = The amount of the ordinary cash dividend
or the special cash dividend, as the case may
be
Miscellaneous
- -------------
Transfer : Neither party may transfer the Transaction, in whole
or in part, without the prior written consent of the
non-transferring party.
Account Details
- ---------------
Payments and deliveries to Party A:
Account for payments: Previously Provided
Delivery instructions: Previously Provided
Payments and deliveries to Party B:
Account for payments: Previously Provided
Delivery instructions: Previously Provided
Please confirm that the foregoing correctly sets forth the terms of our
agreement by executing the copy of this Confirmation enclosed for that purpose
and returning it to us or by sending to us a letter or telex substantially
similar to this letter, which letter or telex sets forth the material terms of
the Transaction to which this Confirmation relates and indicates your agreement
to those terms.
Yours sincerely,
SWISS BANK CORPORATION, LONDON BRANCH
By: /s/ Victoria Harkness Sotgiu By: /s/ John Marshall
----------------------------- ----------------------------
Name: Victoria Harkness Sotgiu Name: John Marshall
Title: Authorised Signatory Title: Authorised Signatory
Confirmed as of the 22nd day
of October, 1997
MYRIAD GENETICS, INC.
By: /s/ Jay M. Moyes
------------------------------
Name: Jay M. Moyes
Title: C.F.O.
Exhibit 11.1
------------
MYRIAD GENETICS, INC.
STATEMENT REGARDING COMPUTATION OF NET LOSS PER SHARE
Three Months Ended
September 30, 1997 September 30, 1996
------------------ ------------------
Net loss ($1,795,801) ($2,830,079)
Weighted average common shares outstanding 9,237,843 8,712,829
----------- -----------
Net loss per share ($0.19) ($0.32)
=========== ===========
5
3-MOS
JUN-30-1998
JUL-01-1997
SEP-30-1997
20,447,227
41,351,980
516,139
0
0
51,571,393
15,924,545
3,824,875
74,623,093
9,949,691
0
0
0
92,662
64,543,522
74,623,093
409,545
5,924,587
235,999
8,573,864
0
0
11,448
(1,795,801)
0
(1,795,801)
0
0
0
(1,795,801)
(.19)
(.19)